

Figure 8. The HA-IFN α expression cassette in pSAC35. The expression cassette comprises

PRB1 promoter, from S. cerevisiae.

Fusion leader, first 19 amino acids of the HA leader followed by the last 6 amino acids of the MF α -1 leader.

HA-IFNa coding sequence with a double stop codon (TAATAA) ADH1 terminator, from S. cerevisiae. Modified to remove all the coding sequence normaly present in the Hind III/BamHI fragment generally used.

Figure 8

Localisation of 'Loops' based on the HA Crystal Structure which could be used for Mutation/Insertion

1		FKDLGEENFK HHH HHH						
	-			II				
	I				III			
51	KTCV ADESAE HHHHH	NCDKSLHTLF HHHHH		RETYGEMADC HHHH				
101	CFLQHKDDNP HHHH	NLPRLVRPEV H	DVMCTAFHDN HHHHHHHH					
			IV					
151		ҮКААГТЕСС <mark>О</mark> НННННННН	AADKAA CLLP					
		•			V			
201	ASLQKFGERA HHHHH HH	FKAWAVARLS ННИННИНННН			VHTECCHGDL			
	*	ν	·I	VII				
251	TECADDRADI	AKYICENODS	TSSKTKECCE	KPIJEKSHCT	AEVENDEMPA			
		ннннн						
301	DLPSLAADFV HHHH	ESKDVCKNYA HHHHHH		LYEYARRHPD HHHHHH	YSVVLLLRLA HHHHHHHH			
•	•	VIII						
351	КТҮЕТТЬЕКС ННИНИНИННИ		AKVFDEFKPL H HHHHH					
		•	•					
,			-		IX			
401	YKĖQNALLVR ННИНИНИННИ	YTKKVPQVST HHHH H			РЕАКРМР САЕ НИНИНИНИ			
	•	; X		xı	•			
4 - 7	DATE CATATALOT	- -) T 17770120137771012			
	ннннннннн		нинининин нинининин	ННННННН ННННННН	A LEVDETYVPK			
501	EFNAETFTFH	ADICTLSEKE HHH HHH						
	•	XII		•				
551	FAAFVEKCC <u>K</u> HHHHHHHH	ADDKET CFAE	EGKKLVAASQ ННННННННН					
					ü			
	II Thr7 III Ala9	54-Asn61 76-Asp89 92-Glu100 .70-Ala176	Loop VII VIII IX X	Glu280-His Ala362-Glu Lys439-Pro Val462-Lys	368 447			
	•	47-Glu252	XI					
		266-Glu277	XII					

Examples of Modifications to Loop IV

a. Randomisation of Loop IV.

IV

151 APELLFFAKR YKAAFTECC<u>O AADKAA</u>CLLP KLDELRDEGK ASSAKQRLKC НИННИНИНИН ИННИНИНИН НИНИН НИНИНИНИН НИНИНИНИН

IV

X represents the mutation of the natural amino acid to any other amino acid. One, more or all of the amino acids can be changed in this manner. This figure indicates all the residues have been changed.

b. Insertion (or replacement) of Randomised sequence into Loop IV.



ΤΛ

The insertion can be at any point on the loop and the length a length where n would typically be 6, 8, 12, 20 or 25.

Figure 10





Figure 11



Disulfide bonds shown in yellow

Figure 12: Loop IV Gln170-Ala176




Figure 13: Tertiary Structure of HA




Figure 14: Schematic Diagram of Possible ScFv Fusions (Example is of a C-terminal fusion to HA

Figure 15A

	0.0	0 0	0	0 0	0 0	0 0	0 0
¥ 60 20	120 40	1 180 60	r 240 80	100	r 360	r 420 140	160
AAA K	GTA V	GAP	CIT. L,	GAA E	GTT V	TAT Y	AĠG. R
TTC F	CAT H	TCA GCT GAA 1 S A E 6	TTA TGC ACA GTT GCA ACT	GAA CCT GAG AGA AAT E P E R N	GAG	TTA TAT L Y	GCT AAA AGG
AAT N	GAT D	TCA	GCA A	AGA R	AGA CCA R P	ÀC .	GCT
GAA GAA E E	GAA E	GAG E	GTT V	GAG	AGA R	3 AAA AAA T K K Y	TTT F
GAA E	TTT F	GAT	ACA T	CCT	GTG V	AAA K	TTC
GGA G	CCA	GCT A	TGC	GAA E	TTG	T.I.	CCT TAC TIT TAT GCC CCG GAA CTC CTT
CGG TTT AAA GAT TTG GGA R F K D L G	TGT	GTT GCT GAT GAG T V A D E S	TTA L	GGT GAA ATG GCT GAC TGC TGT GCA AAA CAA G E M A D C C A K Q	K	TTT	CTC L
GAT D	CAG Q	TGT C	AAA K	AAA K	CCC	ACA T	GAA E
AAA K	TAT CTT CAG CAG T	GAA TTT GCA AAA ACA TGT E F A K T C	I TTT GGA GAC AAA T F G D K L	GCA A	CTC CCC (CAT GAC AAT GAA GAG ACA H D N E E T	CCG
TTT F	CTT	AAA K	GGA G	TGT	AAC N	GAA E	, GCC A
CGG R	TAT Y	GCA A	TTT F	TGC	CCA AAC O	AAT N	TAT
CAT H	. CAG	T'TT F	AAA TCA CTT CAT ACC CTT K S L H T L	gác D	CAC AAA GAT GAC AAC H K D D N	GAC D	TTT
GTT GCT	TTT GCT (F	gaa E	ACC	GCT	GAC	CAT H	TAC
GTT V	TTT	ACT T	CAT H	ATG	GAT D	TTT	CCT
GAG E	GCC	GTA V	CTT	GAA E	AAA K	GCŢ A	CAT H
AGT S	AÌT I	GAA E	TCA S	GGT	CAC	ACT GCT T A	AGA R
AAG K	TTG	AAT N	AAA K	TAT	CAA Q	TGC C	AGA R
GCA CAC	TTG GTG	$_{\rm GTG}$	GAC D	r gaa acc tat g	TTG	ATG M	ATT GCC AGA AGA CAT
GCA A	TTG	$ ext{TTA}$	TGT	GAA E	TTC :	GTG	ATT
1 GAT 1 D	GCC	aaa K	AAT N	CGT	TGC	GAT D	GAA E
러 근	21	121	181	241	301	361	421

540 180	600	660 220	720 240	780 260	840 280	300	960 320
CCA P	дда ТСТ 600 К С 200	AGC S	AAA. 720 K 240	GAC CTT D L	TGT GAA 840 C E 280	CCT GCT	TAT GCT Y
$\overset{\text{TTG}}{\stackrel{\cdot}{\text{L}}}$	AAA K	$^{ m CTG}_{ m L}$	ACC T	GAC D	$^{\mathrm{TGT}}_{\mathcal{C}}$	CCT	TÀT Y
CTG L	CTC	260	$_{\rm L}^{\rm CTT}$	GCG A	TGC	ATG M	AAC
TGC	CAG AGA Q R	GTG GCT (V	GAT CTT D	AGG R	AAG GAA TGC 1 K· E C C	GAG E	GTT TGC AAA AAC V C K N
GCC A	CAG	GTG V	ACA T	GAC D.	AAG K	GAT D	TGC
GCT A	aaa K	gca a	GTG V	GAT D	AGT AAA CTG A	AAT	GTT V
AAA K	GCC A	· TGG W	L	GCT A	AAA K	GAA E	GCT GAT TTT GTT GAA AGT AAG GAT A D F V E S K D
GAT	TCT	GCA A	AAG K	TGT	AGT	ATT GCC GAA GTG I A E V	AAG K
GCT A	TCG	AAA K	TCC	GAA E	rcc 3	GAA E	AGT S
GCT	GCT	TTC	GTT V	, CTT L	ATC I	GCC A	GAA
CAA Q	AAG K	GCT.	GAA	CTG CTT L	TCG ATC	ATT I	GTT V
TGC		AGA R	GCA A	GAT D	BAT O	TGC C	TTT
TGT	GAA	GAA E	TTT F	CAT GGA H	AAT CAG O	TCC CAC	GAT
GAA E	GAT D	GGA	GAG	CAT H	AAT N	TCC S	GCT A
ACA	CGG R	C CAA AAA TIT GGA Gi Q K F G E	GCT	ט ט	GAA E	AAA K	TCA TTA GCT (S L A I
TTT	CTT L	AAA K	AAA K	GAA TGC 1 E C C	TGT	TTG GAA I L E I	TTA L
GCT A	GAA E	CAA	CCC P	GAA E	ATC	TTG L	TCA S
GCT A	GA D	CŢ L	TTT	ACG T	TAT	CTG	CCI
AAA K	CTC L	AGT S	AGA R	CAC H	AAG K	CCT	TTG
$_{\rm Y}^{\rm TAT}$	AAG K	GCC A	CAG	GTC V	GCC	AAA K	GAC TTG D L
481 161	541 181	601 201	661	721	781 261	841	901 301
-	•						

Figure 15B

1020 1380 CITTCA S AAA GGA G aaa K ${\tt GTG}$ $^{\mathrm{TGT}}_{\mathcal{C}}$ CTT L AGG $_{
m LGL}$ TTT F Ø ĸ ACT AGA GAG E gaa E GAT D AGC GAA TTC . GĠC $_{
m GTG}$ GAG E AAG K \mathtt{GTG} CTA AAA ACC T TAT $_{
m TAT}$ $_{\rm C}^{\rm TGT}$ aaa K AAG gcc AAC N TAC GAC GGA ט \mathtt{TAT} CAA Q CIA CGT闰 出 AAC N AAA K AGA GAA E \mathtt{TCA} CAT H Д GIC CCT AAT N GCG A GICAAT N GAG E GAT D CAG Q GATGCA CAG Q GTA CCT P Ø × А AAG GCT A GAG E GCA A GCA GCC A GAA E ACT T H GAG GŢĠ V TAC Y CCA P TGT C CCT D4 1201 401 1081 361 1141 381 1261 421 1321 341 441

Figure 15C

GAC

1500 500		1620	540	1680 560	1740580	
ĄAA. K	GAG R	ند	E-i	AAG K	CTT GTT GCT GCA AGT CAA L V A A S Q	
CCC	AAG K	GCA	A.	TGC TGC AAG C C K	AGT S	
GTT V	GAG	AAG	×	TGC C	GCA	
${\tt TAC}_{\rm Y}$	TCT		ч .	AAG K	GCT.	
ACA	CTT	AAG	×	GTA GAG V E	GTT	
GAA E		CAC	Ħ	GTA V	CIT	1782
GAT D	TGC	GTG AAA CAC AAG CCC	₩ .	GCT TTT GTA GAG AAG 'A F V E K	AAA AAA K K	CAG
GŢĊ	ATA	GTG	>	GCT	AAA K	$_{ m TCT}$
GAA E	GAT	CTT	ъ	GCA A	GGT	GCA
GCT. CTG	GCA	AAA CAA ACT GCA CTT GTT GAG CTT	臼	GAT TTC D F	GAG GAG E E	TTA AAA
GCT		GTT.	· >	GAT D		
TCA	TTC	CTT	⊢	GCT GTT ATG GAT A V M D	TTT GCC F A	CAT CTA CAT
TTT. F	ACC	GCA	A	ATG	TTT F	CTA
TGC	· TTC	ACT		GTT V	TGC	CAT
CCA P	ACA	: CAA	a	GCT.	ACC	TAA
CGA R		AAA	¥	AAA K	GAG E	TTA
AGG R	GCT	ATC AAG	x .	CAA CTG Q L	AAG K	TTA GGC
GTG AAC V N	AAT	ATC	Н	CAA Q	GAT	
		CAA	0	GAG	GAC	GCC
TTG	GAG		ద	AAA K	GCT A	GCT
1441			. 521	1621 541	1681 561	1741
,	•					

Figure 15D

ᇊ

Ö

H,

ø,

581 A

SEQUENCE LISTING

```
<110> Delta Biotechnology Limited
       Principia Pharmaceutical Corporation
 <120> Albumin Fusion Proteins
 <130> PF542PCT
 <140> Unassigned
 <141> 2001-04-12
 <150> 60/229,358
 <151> 2000-04-12
 <150> 60/256,931
<151> 2000-12-21
 <150> 60/199,384
 <151> 2000-04-25
 <160> 37
 <170> PatentIn Ver. 2.1
 <210> 1
 <211> 23
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221> primer_bind
 <223> primer useful to clone human growth hormone cDNA
 <400> 1
 cccaagaatt cccttatcca ggc
                                                                    23
 <210> 2
 <211> 33
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221> primer_bind
 <223> primer useful to clone human growth hormone cDNA
                                                                    33
 gggaagctta gaagccacag gatccctcca cag
 <210> 3
 <211> 16
 <212> DNA
 <213> Artificial Sequence
 <220>
```

```
<221> misc_structure
<223> synthetic oligonucleotide used to join DNA fragments
with non-cohesive ends.
<400> 3
                                                                   16
gataaagatt cccaac
<210> 4
<211> 17
<212> DNA
<213> Artificial Sequence
<220>
<221> misc_structure
<223> synthetic oligonucleotide used to join DNA fragments
with non-cohesive ends.
<400> 4
                                                                   17
aattgttggg aatcttt
<210> 5
<211> 17
<212> DNA
<213> Artificial Sequence
<220>
<221> misc_structure
<223> synthetic oligonucleotide used to join DNA fragments
with non-cohesive ends.
<400> 5
                                                                   17
ttaggcttat tcccaac
<210> 6
<211> 18
<212> DNA
<213> Artificial Sequence
<220>
<221> misc_structure
<223> synthetic oligonucleotide used to join DNA fragments
with non-cohesive ends.
<400> 6
                                                                   18
aattgttggg aataagcc
<210> 7
<211> 24
<212> PRT
<213> Artificial Sequence
<220>
<221> SITE
<222> 1)..(19)
<223> invertase leader sequence
```

```
<220>
<221> SITE
<222> 20)..(24)
<223> first 5 amino acids of mature human serum albumin
Met Leu Leu Gln Ala Phe Leu Phe Leu Leu Ala Gly Phe Ala Ala Lys
                                     10
Ile Ser Ala Asp Ala His Lys Ser
             20
<210> 8
<211> 21
<212> DNA
<213> Artificial Sequence
<220>
<221> misc_structure
<223> synthetic oligonucleotide used to join DNA
fragments with non-cohesive ends.
<400> 8
                                                                   21
gagatgcaca cctgagtgag g
<210> 9
<211> 27
<212> DNA
<213> Artificial Sequence
<220>
<221> misc_structure
<223> synthetic oligonucleotide used to join DNA
fragments with non-cohesive ends.
<400> 9
                                                                   27
gatcctgtgg cttcgatgca cacaaga
<210> 10
<211> 24
<212> DNA
<213> Artificial Sequence
<221> misc_structure
<223> synthetic oligonucleotide used to join DNA
fragments with non-cohesive ends.
<400> 10
                                                                   24
ctcttgtgtg catcgaagcc acag
<210> 11
<211> 30
<212> DNA
```

<213> Artificial Sequence

```
<220>
<221> misc_structure
<223> synthetic oligonucleotide used to join DNA
fragments with non-cohesive ends.
<400> 11
                                                                   30
tgtggaagag cctcagaatt tattcccaac
<210> 12
<211> 31
<212> DNA
<213> Artificial Sequence
<220>
<221> misc_structure
<223> synthetic oligonucleotide used to join DNA
fragments with non-cohesive ends.
<400> 12
aattgttggg aataaattct gaggctcttc c
                                                                   31
<210> 13
<211> 47
<212> DNA
<213> Artificial Sequence
<220>
<221> misc_structure
<223> synthetic oligonucleotide used to join DNA
fragments with non-cohesive ends.
<400> 13
ttaggcttag gtggcggtgg atccggcggt ggtggatctt tcccaac
                                                                   47
<210> 14
<211> 48
<212> DNA
<213> Artificial Sequence
<220>
<221> misc_structure
<223> synthetic oligonucleotide used to join DNA
fragments with non-cohesive ends.
<400> 14
                                                                   48
aattgttggg aaagatccac caccgccgga tccaccgcca cctaagcc
<210> 15
<211> 62
<212> DNA
<213> Artificial Sequence
<220>
<221> misc_structure
<223> synthetic oligonucleotide used to join DNA
fragments with non-cohesive ends.
```

)> 15 ggctt		gcggt	ggt	gg at	ctg	gtggd	c gg(cggat	ctg	gtgg	gaggt	gg a	atcci	tccca	60 62
<213	0> 16 1> 63 2> Di 3> Ai	1 7 3	icial	l Sed	quenc	ce							·			
<220> <221> misc_structure <223> synthetic oligonucleotide used to join DNA fragments with non-cohesive ends.																
<400> 16 aattgttggg aaggatccac cgccaccaga tccgccgcca ccagatccac caccgcctaa gcc													60 63			
<213	0> 1: l> 1: 2> Di 3> Ho	782 NA	sapie	ens												
	l> CI		(1755	5)												
- 4.04	. 15	,														
gat		cac	aag Lys													48
			aaa Lys 20													96
			ttt Phe													144
	_		aca Thr	_	_		_			_	_		_	_		192
			acc Thr				_			_		_	_			240
_	_		tat Tyr		_	_	-	-	_	_	_			-		288
			gaa Glu 100							-						336

										atg Met						384
										tta Leu						432
-						-	-			ctt Leu 155			_			480
			_				_	_		gct Ala	_	_		_	_	528
	_	_		_		-	_			gat Asp	_		_	-		576
	-		_	_			-	-	-	ctc Leu					-	624
~	~			_		_		~	_	ctg Leu	_	_	~			672
	-			-	-	_		-		gtg Val 235		_				720
										ctt Leu						768
		_		_	_			_	_	aat Asn		_	_			816
										ctg Leu						864
_							_		_	cct Pro	_	_	_			912
	-	-	-		-	_	-	-	_	gtt Val 315	_				-	960
	_	_		-		_		-		ttg Leu		_		-	_	1008
										ctg Leu						1056

tat gaa acc Tyr Glu Thr 355	Thr Leu Gl			Ala Ala			1104
tgc tat gcc Cys Tyr Ala 370		_					1152
cag aat tta Gln Asn Leu 385		n Asn Cys			-		1200
tac aaa tto Tyr Lys Phe					_		1248
caa gtg tca Gln Val Ser		r Leu Val	-			-	1296
gtg ggc ago Val Gly Ser 435	Lys Cys Cy		-	Ala Lys	-		1344
gca gaa gac Ala Glu Asp 450			-	-		-	1392
gag aaa acg Glu Lys Thr 465		r Asp Arg	_	_	_		1440
ttg gtg aac Leu Val Asn		-	_		-	-	1488
tac gtt ccc Tyr Val Pro			_				1536
ata tgc aca Ile Cys Thr 515	Leu Ser Gl		_	Ile Lys		_	1584
ctt gtt gag Leu Val Glu 530							1632
aaa gct gtt Lys Ala Val 545		p Phe Ala	-				1680
gct gac gat Ala Asp Asp							1728
gct gca agt Ala Ala Ser				catctac a	tttaaaag	yc atctcag	1782

<210> 18

<211> 585

<212> PRT

<213> Homo Sapiens

<400> 18

Asp Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu 1 5 10 15

Glu Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln 20 25 30

Gln Cys Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu 35 40 45

Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys 50 60

Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu 65 70 75 80

Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro
85 90 95

Glu Arg Asn Glu Cys Phe Leu Gln His Lys Asp Asp Asn Pro Asn Leu 100 105 110

Pro Arg Leu Val Arg Pro Glu Val Asp Val Met Cys Thr Ala Phe His 115 120 125

Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg

Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg 145 150 155 160

Tyr Lys Ala Ala Phe Thr Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala 165 170 175

Cys Leu Leu Pro Lys Leu Asp Glu Leu Arg Asp Glu Gly Lys Ala Ser 180 185 190

Ser Ala Lys Gln Arg Leu Lys Cys Ala Ser Leu Gln Lys Phe Gly Glu 195 200 205

Arg Ala Phe Lys Ala Trp Ala Val Ala Arg Leu Ser Gln Arg Phe Pro 210 215 220

Lys Ala Glu Phe Ala Glu Val Ser Lys Leu Val Thr Asp Leu Thr Lys 225 230 235 240

Val His Thr Glu Cys Cys His Gly Asp Leu Leu Glu Cys Ala Asp Asp 245 250 255

Arg Ala Asp Leu Ala Lys Tyr Ile Cys Glu Asn Gln Asp Ser Ile Ser 260 265 270

Ser Lys Leu Lys Glu Cys Cys Glu Lys Pro Leu Leu Glu Lys Ser His 275 280 285

Cys	Ile 290	Ala	Glu	Val	Glu	Asn 295	Asp	Glu	Met	Pro	Ala 300	Asp	Leu	Pro	Ser
Leu 305	Ala	Ala	Asp	Phe	Val 310	Glu	Ser	Lys	Asp	Val 315	Суз	Lys	Asn	Tyr	Ala 320
Glu	Ala	Lys	Asp	Val 325	Phe	Leu	Gly	Met	Phe 330	Leu	Tyr	Glu	Tyr	A1a 335	Arg
Arg	His	Pro	Asp 340	Tyr	Ser	Va1	Val	Leu 345	Leu	Leu	Arg	Leu	Ala 350	Lys	Thr
Tyr	Glu	Thr 355	Thr	Leu	Glu	Lys	Cys 360	Cys	Ala	Ala	Ala	Asp 365	Pro	His	Glu
Cys	Tyr 370	Ala	Lys	Val	Phe	Asp 375	Glu	Phe	Lys	Pro	Leu 380	Val	Glu	Glu	Pro
Gln 385	Asn	Leu	Ile	Lys	Gln 390	Asn	Cys	Glu	Leu	Phe 395	Glu	Gln	Leu	Gly	Glu 400
Tyr	Lys	Phe	Gln	Asn 405	Ala	Leu	Leu	Val	Arg 410	Tyr	Thr	Lys	Lys	Val 415	Pro
Gln	Val	Ser	Thr 420	Pro	Thr	Leu	Val	Glu 425	Val	Ser	Arg	Asn	Leu 430	Gly	Lys
Val	Gly	Ser 435	Lys	Cys	Cys	Lys	His 440	Pro	Glu	Ala	Lys	Arg 445	Met	Pro	Cys
Ala	Glu 450	Asp	Tyr	Leu	Ser	Val 455	Val	Leu	Asn	Gln	Leu 460	Cys	Val	Leu	His
Glu 465	Lys	Thr	Pro	Val	Ser 470	Asp	Arg	Val	Thr	Lys 475	Cys	Cys	Thr	Glu	Ser 480
Leu	Val	Asn	Arg	Arg 485	Pro	Cys	Phe	Ser	Ala 490	Leu	Glu	Val	Asp	Glu 495	Thr
Tyr	Val	Pro	Lys 500	Glu	Phe	Asn	Ala	Glu 505	Thr	Phe	Thr	Phe	His 510	Ala	Asp
Ile	Cys	Thr 515	Leu	Ser	Glu	Lys	Glu 520	Arg	Gln	Ile	Lys	Lуs 525	Gln	Thr	Ala
Leu	Val 530	Glu	Leu	Val	Lys	His 535	Lys	Pro	Lys	Ala	Thr 540	Lys	Glu	Gln	Leu
Lys 545	Ala	Val	Met	Asp	Asp 550	Phe	Ala	Ala	Phe	Val 555	Glu	Lys	Cys	Cys	Lys 560
Ala	Asp	Asp	Lys	Glu 565	Thr	Cys	Phe	Ala	Glu 570	Glu	Gly	Lys	Lys	Leu 575	Val
Ala	Ala	Ser	Gln 580	Ala	Ala	Leu	Gly	Leu 585							

```
<210> 19
<211> 57
<212> DNA
<213> Artificial Sequence
<220>
<221> primer_bind
<223> primer used to generate XhoI and ClaI
site in pPPC0006
<400> 19
gcctcgagaa aagagatgca cacaagagtg aggttgctca tcgatttaaa gatttgg
                                                                   57
<210> 20
<211> 58
<212> DNA
<213> Artificial Sequence
<220>
<221> primer_bind
<223> primer used in generation XhoI and ClaI
site in pPPC0006
<400> 20
aatcgatgag caacctcact cttgtgtgca tctcttttct cgaggctcct ggaataag
                                                                   58
<210> 21
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<221> primer_bind
<223> primer used in generation XhoI and ClaI
site in pPPC0006
<400> 21
tacaaactta agagtccaat tagc
                                                                    24
<210> 22
<211> 29
<212> DNA
<213> Artificial Sequence
<220>
<221> primer_bind
<223> primer used in generation XhoI and ClaI
site in pPPC0006
<400> 22
cacttctcta gagtggtttc atatgtctt
                                                                    29
<210> 23
<211> 60
<212> DNA
<213> Artificial Sequence
```

```
<220>
<221> Misc_Structure
<223> Synthetic oligonucleotide used to alter restriction
sites in pPPC0007
<400> 23
aagetgeett aggettataa taaggegege eggeeggeeg tttaaactaa gettaattet 60
<210> 24
<211> 60
<212> DNA
<213> Artificial Sequence
<220>
<221> Misc_Structure
<223> Synthetic oligonucleotide used to alter restriction
sites in pPPC0007
<400> 24
agaattaagc ttagtttaaa cggccggccg gcgcgcctta ttataagcct aaggcagctt 60
<210> 25
<211> 32
<212> DNA
<213> Artificial Sequence
<220>
<221> primer_bind
<223> forward primer useful for generation of albumin
fusion protein in which the albumin moiety is N-terminal
of the Therapeutic Protein
<220>
<221> misc_feature
<222> (18)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (19)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (20)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (21)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (22)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc_feature
<222> (23)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (24)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (25)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (26)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (27)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (28)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (29)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (30)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (31)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (32)
<223> n equals a,t,g, or c
                                                                   32
aagctgcctt aggcttannn nnnnnnnnn nn
<210> 26
<211> 51
<212> DNA
<213> Artificial Sequence
<220>
<221> primer_bind
```

<223> reverse primer useful for generation of albumin fusion protein in which the albumin moiety is N-terminal

```
of the Therapeutic Protein
<220>
<221> misc_feature
<222> (37)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (38)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (39)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (40)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (41)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (42)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (43)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (44)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (45)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (46)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (47)
<223> n equals a,t,g, or c
<220>
```

```
<221> misc_feature
<222> (48)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (49)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (50)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (51)
<223> n equals a,t,g, or c
<400> 26
gcgcgcgttt aaacggccgg ccggcgcgcc ttattannnn nnnnnnnnn n
                                                                   51
<210> 27
<211> 33
<212> DNA
<213> Artificial Sequence
<220>
<223> forward primer useful for generation of albumin fusion
protein in which the albumin moiety is c-terminal of the
Therapeutic Protein
<220>
<221> misc_feature
<222> (19)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (20)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (21)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (22)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (23)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
```

```
222> (24)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (25)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (26)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (27)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (28)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (29)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (30)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (31)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
222> (32)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (33)
<223> n equals a,t,g, or c
<400> 27
aggagcgtcg acaaaagann nnnnnnnnn nnn
                                                                    33
<210> 28
<211> 52
<212> DNA
<213> Artificial Sequence
<220>
<221> primer_bind
<223> reverse primer useful for generation of albumin
```

fusion protein in which the albumin moiety is c-terminal of the Therapeutic Protein

```
<220>
<221> misc_feature
<222> (38)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (39)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (40)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (41)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (42)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (43)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (44)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (45)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (46)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (47)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (48)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
```

```
<222> (49)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (50)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (51)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (52)
<223> n equals a,t,g, or c
<400> 28
ctttaaatcg atgagcaacc tcactcttgt gtgcatcnnn nnnnnnnnn nn
                                                                  52
<210> 29
<211> 24
<212> PRT
<213> Artificial Sequence
<220>
<221> signal
<223> signal peptide of natural human serum albumin protein
Met Lys Trp Val Ser Phe Ile Ser Leu Leu Phe Leu Phe Ser Ser Ala
                  5
Tyr Ser Arg Ser Leu Asp Lys Arg
<210> 30
<211> 114
<212> DNA
<213> Artificial Sequence
<220>
<221> primer_bind
<223> forward primer useful for generation of PC4:HSA
albumin fusion VECTOR
<220>
<221> misc_feature
<222> (5)..(10)
<223> BamHI retsriction site
<220>
<221> misc_feature
<222> (11)..(16)
<223> Hind III retsriction site
<221> misc_feature
```

```
<222> (17)..(27)
<223> Kozak sequence
<220>
<221> misc_feature
<222> (25)..(97)
<223> cds natural signal sequence of human serum albumin
<220>
<221> misc_feature
<222> (75)..(81)
<223> XhoI restriction site
<220>
<221> misc_feature
<222> (98)..(114)
<223> cds first six amino acids of human serum albumin
<400> 30
tcagggatcc aagcttccgc caccatgaag tgggtaacct ttatttccct tctttttctc 60
tttagctcgg cttactcgag gggtgtgttt cgtcgagatg cacacaagag tgag
                                                                  114
<210> 31
<211> 43
<212> DNA
<213> Artificial Sequence
<220>
<221> primer_bind
<223> reverse primer useful for generation of
PC4:HSA albumin fusion VECTOR
<220>
<221> misc_feature
<222> (6)..(11)
<223> Asp718 restriction site
<220>
<221> misc_feature
<222> (12)..(17)
<223> EcoRI restriction site
<220>
<221> misc_feature
<222> (15)..(17)
<223> reverse complement of stop codon
<220>
<221> misc_feature
<222> (18)..(25)
<223> AscI restriction site
<220>
<221> misc_feature
<222> (18)..(43)
<223> reverse complement of DNA sequence encoding last 9 amino acids
<400> 31
```

43

gcagcggtac cgaattcggc gcgccttata agcctaaggc agc <210> 32 <211> 46 <212> DNA <213> Artificial Sequence <220> <221> primer_bind <223> forward primer useful for inserting Therapeutic protein into pC4:HSA vector <220> <221> misc_feature <222> (29) <223> n equals a,t,g, or c <220> <221> misc_feature <222> (30) <223> n equals a,t,g, or c <220> <221> misc_feature <222> (31) <223> n equals a,t,g, or c <220> <221> misc_feature <222> (32) <223> n equals a,t,g, or c <220> <221> misc_feature <222> (33) <223> n equals a,t,g, or c <220> <221> misc_feature <222> (34) <223> n equals a,t,g, or c <220> <221> misc_feature <222> (35) <223> n equals a,t,g, or c <220> <221> misc_feature <222> (36) <223> n equals a,t,g, or c <220> <221> misc_feature <222> (37) <223> n equals a,t,g, or c <220> <221> misc_feature

<222> (38)

```
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (39)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (40)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (41)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (42)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (43)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (44)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (45)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (46)
<223> n equals a,t,g, or c
<400> 32
                                                                   46
ccgccgctcg aggggtgtgt ttcgtcgann nnnnnnnn nnnnnn
<210> 33
<211> 55
<212> DNA
<213> Artificial Sequence
<220>
<221> primer_bind
<223> reverse primer useful for inserting Therapeutic
protein into pC4:HSA vector
<220>
<221> misc_feature
<222> (38)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc_feature
<222> (39)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (40)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (41)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (42)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (43)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (44)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (45)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (46)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (47)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (48)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (49)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (50)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc_feature
<222> (51)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (52)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (53)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (54)
<223> n equals a,t,g, or c
<220>
<221> misc_feature
<222> (55)
<223> n equals a,t,g, or c
<400> 33
agtcccatcg atgagcaacc tcactcttgt gtgcatcnnn nnnnnnnnnn nnnnn
                                                                  55
<210> 34
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<221> signal
<223> Stanniocalcin signal peptide
Met Leu Gln Asn Ser Ala Val Leu Leu Leu Val Ile Ser Ala Ser
                                     10
Ala
<210> 35
<211> 22
<212> PRT
<213> Artificial Sequence
<220>
<221> signal
<223> Synthetic signal peptide
Met Pro Thr Trp Ala Trp Trp Leu Phe Leu Val Leu Leu Ala Leu
                                     10
Trp Ala Pro Ala Arg Gly
             20
<210> 36
```

<211> 66

<212> PRT

<213> Agkistrodon piscivorus

<400> 36

Ile Thr Tyr Thr Asp Cys Thr Glu Ser Gly Gln Asn Leu Cys Leu Cys $1 \hspace{1cm} 5 \hspace{1cm} 10 \hspace{1cm} 15$

Glu Gly Ser Asn Val Cys Gly Lys Gly Asn Lys Cys Ile Leu Gly Ser 20 25 30

Gln Gly Lys Asp Asn Gln Cys Val Thr Gly Glu Gly Thr Pro Lys Pro 35 40 45

Gln Ser His Asn Gln Gly Asp Phe Glu Pro Ile Pro Glu Asp Ala Tyr 50 55 60

Asp Glu 65

<210> 37

<211> 71

<212> PRT

<213> Agkistrodon piscivorus

<400> 37

Glu Ala Gly Glu Glu Cys Asp Cys Gly Ser Pro Glu Asn Pro Cys Cys
1 10 15

Asp Ala Ala Thr Cys Lys Leu Arg Pro Gly Ala Gln Cys Ala Glu Gly 20 25 30

Leu Cys Cys Asp Gln Cys Lys Phe Met Lys Glu Gly Thr Val Cys Arg 35 40 45

Ala Arg Gly Asp Asp Val Asn Asp Tyr Cys Asn Gly Ile Ser Ala Gly 50 60

Cys Pro Arg Asn Pro Phe His

INTERNATIONAL SEARCH REPORT

In.....nal application No.
PCT/US01/12009

	<u> </u>	
A. CLASSIFICATION OF SUBJECT MATTER IPC(7) :C07K 14/00; C07H 21/04; C12N 15/00; A61K 38 US CL : 435/320.1; 514/2; 530/350; 536/23.4 According to International Patent Classification (IPC) or to bot	•	
	iii iiiiiiiiiiii olussiiiourion and ii	
B. FIELDS SEARCHED Minimum documentation searched (classification system follow	ed by classification symbols)	
U.S. : 435/320.1; 514/2; 530/350; 536/23.4	,	
Documentation searched other than minimum documentation to the	re extent that such documents are included in	the fields searched
Electronic data base consulted during the international search (number of the median search terms: chimera, fusion, human serum albumin, interference of the median service of t	e databases	į
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category* Citation of document, with indication, where	appropriate, of the relevant passages	Relevant to claim No.
X WO 99/66054 A2 (GENZYME 'December 1999, see entire document		1,2,4,6,9,10,12,1 4,16,17,24,28,30- 37,40-42
		3,15,25,26,29,39 N
X WO 97/24445 A1 (DELTA BIOTEC 1997, seen entire document, especial)		1-4,6,9,10,13- 17,25,28- 34,36,37,39-42
		5,7,8,24,26,2 7,35,38
X Further documents are listed in the continuation of Box	C. See patent family annex.	
* Special categories of cited documents: "A" document defining the general state of the art which is not considere	"T" later document published after the induced date and not in conflict with the appear the principle or theory underlying the	lication but cited to understand
to be of particular relevance "E" earlier document published on or after the international filing date	"X" document of particular relevance; il considered novel or cannot be considered when the document is taken alone	
"L" document which may throw doubts on priority claim(s) or which of oited to establish the publication date of another citation or other special reason (as specified)	document of particular relevance; the considered to involve an inventive	e step when the document is
"O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later that	being obvious to a person skilled in	the art
Date of the actual completion of the international search	Date of mailing of the international se	
16 JULY 2001	22 AUG	
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231	BRONWEN M. LOFARALEGA	
Facsimile No. (703) 305-3230	Telephone No. (703) TECH BOLOG	y Center 1600

INTERNATIONAL SEARCH REPORT

International application No. PCT/US01/12009

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
Catogory	Citation of document, with manager, when appropriate	
ζ	US 5,705,363 A (IMAKAWA, K.) 6 January 1998, see entire document, especially col. 23, line 44-col. 24, line 56.	1,2,4,5-7,10,2 5,33-38,40-42
Ĭ.		3,14,15,16,17,24,
X	US 5,766,883 A (BALLANCE et al) 16 June 1998, see entire document, especially col.1, line 38-54, col. 6, line 53-col 10, line 41, col. 11, line 36-col. 12, line 40.	1,2,4,6,10,13, 14,25,30- 34,36,37,40-42
,		

CORRECTED VERSION

(19) World Intellectual Property Organization

International Bureau





(43) International Publication Date 25 October 2001 (25.10.2001)

PCT

(10) International Publication Number WO 01/79271 A1

- (51) International Patent Classification⁷: C07H 21/04, C12N 15/00, A61K 38/16
- C07K 14/00,
- (21) International Application Number: PCT/US01/12009
- (22) International Filing Date: 12 April 2001 (12.04.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:

60/229,358	12 April 2000 (12.04.2000)	US
60/199,384	25 April 2000 (25.04.2000)	US
60/256,931	21 December 2000 (21.12.2000)	US

- (71) Applicants (for all designated States except US): PRINCIPIA PHARMACEUTICAL CORPORATION [US/US]; 2650 Eisenhower Avenue, Building C, Norristown, PA 19403 (US). DELTA BIOTECHNOLOGY LIMITED [GB/GB]; Castle Court, 59 Castle Boulevard, Nottingham NG7 1FD (GB).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): BALLANCE, David, James [GB/US]; 1113 Cymry Drive, Berwyn, PA 19312 (US). SLEEP, Darrell [GB/US]; 66 Ladybay Road, West Bridgford, Nottingham NG2 5DS (GB). TURNER, Andrew, John [GB/US]; Apartment C-28, 305 Conestoga Way, Eagleville, PA 19408 (US). SADEGHI, Homayoun [US/US]; 320 E. Court Street, Doylestown, PA 18901 (US). PRIOR, Christopher, P. [US/US]; 460 Wyldhaven Road, Rosemont, PA 19010 (US).

- (74) Agents: GARRETT, Arthur, S. et al.; Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, 1300 I Street, NW., Washington, DC 20005-3315 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- with (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description
- (48) Date of publication of this corrected version:

28 February 2002

(15) Information about Correction:

see PCT Gazette No. 09/2002 of 28 February 2002, Section

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



(54) Title: ALBUMIN FUSION PROTEINS

(57) Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

ALBUMIN FUSION PROTEINS

5

10

15

20

.25

30

35

BACKGROUND OF THE INVENTION

The invention relates generally to Therapeutic proteins (including, but not limited to, a polypeptide, antibody, or peptide, or fragments and variants thereof) fused to albumin or fragments or variants of albumin. The invention further relates to Therapeutic proteins (including, but not limited to, a polypeptide, antibody, or peptide, or fragments and variants thereof) fused to albumin or fragments or variants of albumin, that exhibit extended shelf-life and/or extended or therapeutic activity in solution. These fusion proteins are herein collectively referred to as "albumin fusion proteins of the invention." The invention encompasses therapeutic albumin fusion proteins, compositions, pharmaceutical compositions, formulations and kits. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention using these nucleic acids, vectors, and/or host cells.

The invention is also directed to methods of *in vitro* stabilizing a Therapeutic protein via fusion or conjugation of the Therapeutic protein to albumin or fragments or variants of albumin.

Human serum albumin (HSA, or HA), a protein of 585 amino acids in its mature form (as shown in Figure 15 or in SEQ ID NO:18), is responsible for a significant proportion of the osmotic pressure of serum and also functions as a carrier of endogenous and exogenous ligands. At present, HA for clinical use is produced by extraction from human blood. The production of recombinant HA (rHA) in microorganisms has been disclosed in EP 330 451 and EP 361 991.

The role of albumin as a carrier molecule and its inert nature are desirable properties for use as a carrier and transporter of polypeptides *in vivo*. The use of albumin as a component of an albumin fusion protein as a carrier for various proteins has been suggested in WO 93/15199, WO 93/15200, and EP 413 622. The use of N-terminal fragments of HA

Therapeutic protein may be achieved by genetic manipulation, such that the DNA coding for HA, or a fragment thereof, is joined to the DNA coding for the Therapeutic protein. A suitable host is then transformed or transfected with the fused nucleotide sequences, so arranged on a suitable plasmid as to express a fusion polypeptide. The expression may be effected *in vitro* from, for example, prokaryotic or eukaryotic cells, or *in vivo e.g.* from a transgenic organism.

Therapeutic proteins in their native state or when recombinantly produced, such as interferons and growth hormones, are typically labile molecules exhibiting short shelf-lives, particularly when formulated in aqueous solutions. The instability in these molecules when formulated for administration dictates that many of the molecules must be lyophilized and refrigerated at all times during storage, thereby rendering the molecules difficult to transport and/or store. Storage problems are particularly acute when pharmaceutical formulations must be stored and dispensed outside of the hospital environment. Many protein and peptide drugs also require the addition of high concentrations of other protein such as albumin to reduce or prevent loss of protein due to binding to the container. This is a major concern with respect to proteins such as IFN. For this reason, many Therapeutic proteins are formulated in combination with large proportion of albumin carrier molecule (100-1000 fold excess), though this is an undesirable and expensive feature of the formulation.

Few practical solutions to the storage problems of labile protein molecules have been proposed. Accordingly, there is a need for stabilized, long lasting formulations of proteinaceous therapeutic molecules that are easily dispensed, preferably with a simple formulation requiring minimal post-storage manipulation.

SUMMARY OF THE INVENTION

5

10

15

20

25

30

35

The present invention is based, in part, on the discovery that Therapeutic proteins may be stabilized to extend the shelf-life, and/or to retain the Therapeutic protein's activity for extended periods of time in solution, in vitro and/or in vivo, by genetically or chemically fusing or conjugating the Therapeutic protein to albumin or a fragment (portion) or variant of albumin, that is sufficient to stabilize the protein and/or its activity. In addition it has been determined that the use of albumin-fusion proteins or albumin conjugated proteins may reduce the need to formulate protein solutions with large excesses of carrier proteins (such as albumin, unfused) to prevent loss of Therapeutic proteins due to factors such as binding to the container.

The present invention encompasses albumin fusion proteins comprising a Therapeutic protein (e.g., a polypeptide, antibody, or peptide, or fragments and variants thereof) fused to albumin or a fragment (portion) or variant of albumin. The present invention also encompasses albumin fusion proteins comprising a Therapeutic protein (e.g., a polypeptide,

antibody, or peptide, or fragments and variants thereof) fused to albumin or a fragment (portion) or variant of albumin, that is sufficient to prolong the shelf life of the Therapeutic protein, and/or stabilize the Therapeutic protein and/or its activity in solution (or in a pharmaceutical composition) in vitro and/or in vivo. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells.

5

10

15

20

25

30

35

The invention also encompasses pharmaceutical formulations comprising an albumin fusion protein of the invention and a pharmaceutically acceptable diluent or carrier. Such formulations may be in a kit or container. Such kit or container may be packaged with instructions pertaining to the extended shelf life of the Therapeutic protein. Such formulations may be used in methods of treating, preventing, ameliotationg or diagnosing a disease or disease symptom in a patient, preferably a mammal, most preferably a human, comprising the step of administering the pharmaceutical formulation to the patient.

In other embodiments, the present invention encompasses methods of preventing treating, or ameliorating a disease or disorder. In preferred embodiments, the present invention encompasses a method of treating a disease or disorder listed in the "Preferred Indication Y" column of Table 1 comprising administering to a patient in which such treatment, prevention or amelioration is desired an albumin fusion protein of the invention that comprises a Therapeutic protein portion corresponding to a Therapeutic protein (or fragment or variant thereof) disclosed in the "Therapeutic Protein X" column of Table 1 (in the same row as the disease or disorder to be treated is listed in the "Preferred Indication Y" column of Table 1) in an amount effective to treat prevent or ameliorate the disease or disorder.

In another embodiment, the invention includes a method of extending the shelf life of a Therapeutic protein (e.g., a polypeptide, antibody, or peptide, or fragments and variants thereof) comprising the step of fusing or conjugating the Therapeutic protein to albumin or a fragment (portion) or variant of albumin, that is sufficient to extend the shelf-life of the Therapeutic protein. In a preferred embodiment, the Therapeutic protein used according to this method is fused to the albumin, or the fragment or variant of albumin. In a most preferred embodiment, the Therapeutic protein used according to this method is fused to albumin, or a fragment or variant of albumin, via recombinant DNA technology or genetic engineering.

In another embodiment, the invention includes a method of stabilizing a Therapeutic protein (e.g., a polypeptide, antibody, or peptide, or fragments and variants thereof) in solution, comprising the step of fusing or conjugating the Therapeutic protein to albumin or a fragment (portion) or variant of albumin, that is sufficient to stabilize the Therapeutic protein.

In a preferred embodiment, the Therapeutic protein used according to this method is fused to the albumin, or the fragment or variant of albumin. In a most preferred embodiment, the Therapeutic protein used according to this method is fused to albumin, or a fragment or variant of albumin, via recombinant DNA technology or genetic engineering.

The present invention further includes transgenic organisms modified to contain the nucleic acid molecules of the invention, preferably modified to express the albumin fusion proteins encoded by the nucleic acid molecules.

BRIEF DESCRIPTION OF THE FIGURES

5

10

15

20

25

30

35

Figure 1 depicts the extended shelf-life of an HA fusion protein in terms of the biological activity (Nb2 cell proliferation) of HA-hGH remaining after incubation in cell culture media for up to 5 weeks at 37°C. Under these conditions, hGH has no observed activity by week 2.

Figure 2 depicts the extended shelf-life of an HA fusion protein in terms of the stable biological activity (Nb2 cell proliferation) of HA-hGH remaining after incubation in cell culture media for up to 3 weeks at 4, 37, or 50°C. Data is normalized to the biological activity of hGH at time zero.

Figures 3A and 3B compare the biological activity of HA-hGH with hGH in the Nb2 cell proliferation assay. Figure 3A shows proliferation after 24 hours of incubation with various concentrations of hGH or the albumin fusion protein, and Figure 3B shows proliferation after 48 hours of incubation with various concentrations of hGH or the albumin fusion protein.

Figure 4 shows a map of a plasmid (pPPC0005) that can be used as the base vector into which polynucleotides encoding the Therapeutic proteins (including polypeptides and fragments and variants thereof) may be cloned to form HA-fusions. Plasmid Map key: PRB1p: PRB1 S. cerevisiae promoter; FL: Fusion leader sequence; rHA: cDNA encoding HA: ADH1t: ADH1 S. cerevisiae terminator; T3: T3 sequencing primer site; T7: T7 sequencing primer site; Amp R: β-lactamase gene; ori: origin of replication. Please note that in the provisional applications to which this application claims priority, the plasmid in Figure 4 was labeled pPPC0006, instead of pPPC0005. In addition the drawing of this plasmid did not show certain pertinent restriction sites in this vector. Thus in the present application, the drawing is labeled pPPC0005 and more restriction sites of the same vector are shown.

Figure 5 compares the recovery of vial-stored HA-IFN solutions of various concentrations with a stock solution after 48 or 72 hours of storage.

Figure 6 compares the activity of an HA- α -IFN fusion protein after administration to monkeys via IV or SC.

Figure 7 describes the bioavailability and stability of an HA-α-IFN fusion protein.

Figure 8 is a map of an expression vector for the production of HA- α -IFN.

Figure 9 shows the location of loops in HA.

Figure 10 is an example of the modification of an HA loop.

Figure 11 is a representation of the HA loops.

Figure 12 shows the HA loop IV.

5

10

15

20

25

30

. 35

Figure 13 shows the tertiary structure of HA.

Figure 14 shows an example of a scFv-HA fusion

Figure 15 shows the amino acid sequence of the mature form of human albumin (SEQ ID NO:18) and a polynucleotide encoding it (SEQ ID NO:17).

DETAILED DESCRIPTION

As described above, the present invention is based, in part, on the discovery that a Therapeutic protein (e.g., a polypeptide, antibody, or peptide, or fragments and variants thereof) may be stabilized to extend the shelf-life and/or retain the Therapeutic protein's activity for extended periods of time in solution (or in a pharmaceutical composition) in vitro and/or in vivo, by genetically fusing or chemically conjugating the Therapeutic protein, polypeptide or peptide to all or a portion of albumin sufficient to stabilize the protein and its activity.

The present invention relates generally to albumin fusion proteins and methods of treating, preventing, or ameliorating diseases or disorders. As used herein, "albumin fusion protein" refers to a protein formed by the fusion of at least one molecule of albumin (or a fragment or variant thereof) to at least one molecule of a Therapeutic protein (or fragment or variant of a Therapeutic protein and at least a fragment or variant of human serum albumin, which are associated with one another, preferably by genetic fusion (i.e., the albumin fusion protein is generated by translation of a nucleic acid in which a polynucleotide encoding all or a portion of a Therapeutic protein is joined in-frame with a polynucleotide encoding all or a portion of albumin) or chemical conjugation to one another. The Therapeutic protein and albumin protein, once part of the albumin fusion protein, may be referred to as a "portion", "region" or "moiety" of the albumin fusion protein (e.g., a "Therapeutic protein portion" or an "albumin protein portion").

In one embodiment, the invention provides an albumin fusion protein comprising, or alternatively consisting of, a Therapeutic protein (e.g., as described in Table 1) and a serum albumin protein. In other embodiments, the invention provides an albumin fusion protein comprising, or alternatively consisting of, a biologically active and/or therapeutically active fragment of a Therapeutic protein and a serum albumin protein. In other embodiments, the

invention provides an albumin fusion protein comprising, or alternatively consisting of, a biologically active and/or therapeutically active variant of a Therapeutic protein and a serum albumin protein. In preferred embodiments, the serum albumin protein component of the albumin fusion protein is the mature portion of serum albumin.

In further embodiments, the invention provides an albumin fusion protein comprising, or alternatively consisting of, a Therapeutic protein, and a biologically active and/or therapeutically active fragment of serum albumin. In further embodiments, the invention provides an albumin fusion protein comprising, or alternatively consisting of, a Therapeutic protein and a biologically active and/or therapeutically active variant of serum albumin. In preferred embodiments, the Therapeutic protein portion of the albumin fusion protein is the mature portion of the Therapeutic protein. In a further preferred embodiment, the Therapeutic protein portion of the albumin fusion protein is the extracellular soluble domain of the Therapeutic protein. In an alternative embodiment, the Therapeutic protein portion of the albumin fusion protein is the active form of the Therapeutic protein.

In further embodiments, the invention provides an albumin fusion protein comprising, or alternatively consisting of, a biologically active and/or therapeutically active fragment or variant of a Therapeutic protein and a biologically active and/or therapeutically active fragment or variant of serum albumin. In preferred embodiments, the invention provides an albumin fusion protein comprising, or alternatively consisting of, the mature portion of a Therapeutic protein and the mature portion of serum albumin.

Therapeutic proteins

5

10

15

20

25

30

35

As stated above, an albumin fusion protein of the invention comprises at least a fragment or variant of a Therapeutic protein and at least a fragment or variant of human serum albumin, which are associated with one another, preferably by genetic fusion or chemical conjugation.

As used herein, "Therapeutic protein" refers to proteins, polypeptides, antibodies, peptides or fragments or variants thereof, having one or more therapeutic and/or biological activities. Therapeutic proteins encompassed by the invention include but are not limited to, proteins, polypeptides, peptides, antibodies, and biologics. (The terms peptides, proteins, and polypeptides are used interchangeably herein.) It is specifically contemplated that the term "Therapeutic protein" encompasses antibodies and fragments and variants thereof. Thus an albumin fusion protein of the invention may contain at least a fragment or variant of a Therapeutic protein, and/or at least a fragment or variant of an antibody. Additionally, the term "Therapeutic protein" may refer to the endogenous or naturally occurring correlate of a Therapeutic protein.

By a polypeptide displaying a "therapeutic activity" or a protein that is "therapeutically

active" is meant a polypeptide that possesses one or more known biological and/or therapeutic activities associated with a Therapeutic protein such as one or more of the Therapeutic proteins described herein or otherwise known in the art. As a non-limiting example, a "Therapeutic protein" is a protein that is useful to treat, prevent or ameliorate a disease, condition or disorder. As a non-limiting example, a "Therapeutic protein" may be one that binds specifically to a particular cell type (normal (e.g., lymphocytes) or abnormal e.g., (cancer cells)) and therefore may be used to target a compound (drug, or cytotoxic agent) to that cell type specifically.

5

10

15

20 .

. 25

30

35

In another non-limiting example, a "Therapeutic protein" is a protein that has a biological activity, and in particular, a biological activity that is useful for treating preventing or ameliorating a disease. A non-inclusive list of biological activities that may be possessed by a Therapeutic protein includes, enhancing the immune response, promoting angiogenesis, inhibiting angiogenesis, regulating hematopoietic functions, stimulating nerve growth, enhancing an immune response, inhibiting an immune response, or any one or more of the biological activities described in the "Biological Activities" section below.

As used herein, "therapeutic activity" or "activity" may refer to an activity whose effect is consistent with a desirable therapeutic outcome in humans, or to desired effects in non-human mammals or in other species or organisms. Therapeutic activity may be measured in vivo or in vitro. For example, a desirable effect may be assayed in cell culture. As an example, when hGH is the Therapeutic protein, the effects of hGH on cell proliferation as described in Example 1 may be used as the endpoint for which therapeutic activity is measured. Such in vitro or cell culture assays are commonly available for many Therapeutic proteins as described in the art.

Examples of useful assays for particular Therapeutic proteins include, but are not limited to, GMCSF (Eaves, A.C. and Eaves C.J., Erythropoiesis in culture. In: McCullock EA (edt) Cell culture techniques - Clinics in hematology. WB Saunders, Eastbourne, pp 371-91 (1984); Metcalf, D., International Journal of Cell Cloning 10: 116-25 (1992); Testa, N.G., et al., Assays for hematopoietic growth factors. In: Balkwill FR (edt) Cytokines, A practical Approach, pp 229-44; IRL Press Oxford 1991) EPO (bioassay: Kitamura et al., J. Cell. Physiol. 140 p323 (1989)); Hirudin (platelet aggregation assay: Blood Coagul Fibrinolysis 7(2):259-61 (1996)); IFNα (anti-viral assay: Rubinstein et al., J. Virol. 37(2):755-8 (1981); anti-proliferative assay: Gao Y, et al Mol Cell Biol. 19(11):7305-13 (1999); and bioassay: Czarniecki et al., J. Virol. 49 p490 (1984)); GCSF (bioassay: Shirafuji et al., Exp. Hematol. 17 p116 (1989); proliferation of murine NFS-60 cells (Weinstein et al., Proc Natl Acad Sci 83:5010-4 (1986)); insulin (³H-glucose uptake assay: Steppan et al., Nature 409(6818):307-12 (2001)); hGH (Ba/F3-hGHR proliferation assay: J Clin Endocrinol Metab 85(11):4274-9 (2000); International standard for growth hormone: Horm Res, 51

Suppl 1:7-12 (1999)); factor X (factor X activity assay: Van Wijk et al. Thromb Res 22:681-686 (1981)); factor VII (coagulation assay using prothrombin clotting time: Belaaouaj et al., J. Biol. Chem. 275:27123-8(2000); Diaz-Collier et al., Thromb Haemost 71:339-46 (1994)), or as shown in Table 1 in the "Exemplary Activity Assay" column.

5

10

15

20

25

.30

Therapeutic proteins corresponding to a Therapeutic protein portion of an albumin fusion protein of the invention, such as cell surface and secretory proteins, are often modified by the attachment of one or more oligosaccharide groups. The modification, referred to as glycosylation, can dramatically affect the physical properties of proteins and can be important in protein stability, secretion, and localization. Glycosylation occurs at specific locations along the polypeptide backbone. There are usually two major types of glycosylation: glycosylation characterized by O-linked oligosaccharides, which are attached to serine or threonine residues; and glycosylation characterized by N-linked oligosaccharides, which are attached to asparagine residues in an Asn-X-Ser/Thr sequence, where X can be any amino acid except proline. N-acetylneuramic acid (also known as sialic acid) is usually the terminal residue of both N-linked and 0-linked oligosaccharides. Variables such as protein structure and cell type influence the number and nature of the carbohydrate units within the chains at different glycosylation sites. Glycosylation isomers are also common at the same site within a given cell type.

For example, several types of human interferon are glycosylated. Natural human interferon-α2 is O-glycosylated at threonine 106, and N-glycosylation occurs at asparagine 72 in interferon-α14 (Adolf et al., J. Biochem 276:511 (1991); Nyman TA et al., J. Biochem 329:295 (1998)). The oligosaccharides at asparagine 80 in natural interferon-β1α may play an important factor in the solubility and stability of the protein, but may not be essential for its biological activity. This permits the production of an unglycosylated analog (interferon-β1b) engineered with sequence modifications to enhance stability (Hosoi et al., J. Interferon Res. 8:375 (1988; Karpusas et al., Cell Mol Life Sci 54:1203 (1998); Knight, J. Interferon Res. 2:421 (1982); Runkel et al., Pharm Res 15:641 (1998); Lin, Dev. Biol. Stand. 96:97 (1998))1. Interferon-γ contains two N-linked oligosaccharide chains at positions 25 and 97, both important for the efficient formation of the bioactive recombinant protein, and having an influence on the pharmacokinetic properties of the protein (Sareneva et al., Eur. J. Biochem 242:191 (1996); Sareneva et al., Biochem J. 303:831 (1994); Sareneva et al., J. Interferon Res. 13:267 (1993)). Mixed O-linked and N-linked glycosylation also occurs, for example in human erythropoietin, N-linked glycosylation occurs at asparagine residues located at positions 24, 38 and 83 while O-linked glycosylation occurs at a serine residue located at

position 126 (Lai et al., J. Biol. Chem. 261:3116 (1986); Broudy et al., Arch. Biochem. Biophys. 265:329 (1988)).

Therapeutic proteins corresponding to a Therapeutic protein portion of an albumin fusion protein of the invention, as well as analogs and variants thereof, may be modified so that glycosylation at one or more sites is altered as a result of manipulation(s) of their nucleic acid sequence, by the host cell in which they are expressed, or due to other conditions of their expression. For example, glycosylation isomers may be produced by abolishing or introducing glycosylation sites, e.g., by substitution or deletion of amino acid residues, such as substitution of glutamine for asparagine, or unglycosylated recombinant proteins may be produced by expressing the proteins in host cells that will not glycosylate them, e.g. in E. coli or glycosylation-deficient yeast. These approaches are described in more detail below and are known in the art.

5

10

15

20

25

30

35

Therapeutic proteins corresponding to a Therapeutic protein portion of an albumin fusion protein of the invention include, but are not limited to, plasma proteins. specifically, such Therapeutic proteins include, but are not limited to, immunoglobulins, serum cholinesterase, alpha-1 antitrypsin, aprotinin, coagulation factors in both pre and active forms including but not limited to, von Willebrand factor, fibrinogen, factor II, factor VII, factor VIIA activated factor, factor VIII, factor IX, factor X, factor XIII, c1 inactivator, antithrombin III, thrombin, prothrombin, apo-lipoprotein, c-reactive protein, and protein C. Therapeutic proteins corresponding to a Therapeutic protein portion of an albumin fusion protein of the invention further include, but are not limited to, human growth hormone (hGH), α-interferon, erythropoietin (EPO), granulocyte-colony stimulating factor (GCSF), granulocyte-macrophage colony-stimulating factor (GMCSF), insulin, single chain antibodies, autocrine motility factor, scatter factor, laminin, hirudin, applaggin, monocyte chemotactic protein (MCP/MCAF), macrophage colony-stimulating factor (M-CSF), osteopontin, platelet factor 4, tenascin, vitronectin, in addition to those described in Table 1. These proteins and nucleic acid sequences encoding these proteins are well known and available in public databases such as Chemical Abstracts Services Databases (e.g., the CAS Registry), GenBank, and GenSeq as shown in Table 1.

Additional Therapeutic proteins corresponding to a Therapeutic protein portion of an albumin fusion protein of the invention include, but are not limited to, one or more of the Therapeutic proteins or peptides disclosed in the "Therapeutic Protein X" column of Table 1, or fragment or variable thereof.

Table 1 provides a non-exhaustive list of Therapeutic proteins that correspond to a Therapeutic protein portion of an albumin fusion protein of the invention. The "Therapeutic Protein X" column discloses Therapeutic protein molecules followed by parentheses containing scientific and brand names that comprise, or alternatively consist of, that

5

10

15

20

25

30

35

Therapeutic protein molecule or a fragment or variant thereof. "Therapeutic protein X" as used herein may refer either to an individual Therapeutic protein molecule (as defined by the amino acid sequence obtainable from the CAS and Genbank accession numbers), or to the entire group of Therapeutic proteins associated with a given Therapeutic protein molecule disclosed in this column. The "Exemplary Identifier" column provides Chemical Abstracts Services (CAS) Registry Numbers (published by the American Chemical Society) and/or Genbank Accession Numbers ((e.g., Locus ID, NP_XXXXX (Reference Sequence Protein), and XP_XXXXX (Model Protein) identifiers available through the national Center for Biotechnology Information (NCBI) webpage at www.ncbi.nlm.nih.gov) that correspond to entries in the CAS Registry or Genbank database which contain an amino acid sequence of the Therapeutic Protein Molecule or of a fragment or variant of the Therapeutic Protein Molecule. The summary pages associated with each of these CAS and Genbank Accession Numbers are each incorporated by reference in their entireties, particularly with respect to the amino acid sequences described therein. The "PCT/Patent Reference" column provides U.S. Patent numbers, or PCT International Publication Numbers corresponding to patents and/or published patent applications that describe the Therapeutic protein molecule. Each of the patents and/or published patent applications cited in the "PCT/Patent Reference" column are herein incorporated by reference in their entireties. In particular, the amino acid sequences of the specified polypeptide set forth in the sequence listing of each cited "PCT/Patent Reference", the variants of these amino acid sequences (mutations, fragments, etc.) set forth, for example, in the detailed description of each cited "PCT/Patent Reference", the therapeutic indications set forth, for example, in the detailed description of each cited "PCT/Patent Reference", and the activity asssays for the specified polypeptide set forth in the detailed description, and more particularly, the examples of each cited "PCT/Patent Reference" are incorporated herein by reference. The "Biological activity" column describes Biological activities associated with the Therapeutic protein molecule. The "Exemplary Activity Assay" column provides references that describe assays which may be used to test the therapeutic and/or biological activity of a Therapeutic protein or an albumin fusion protein of the invention comprising a Therapeutic protein X portion. Each of the references cited in the "Exemplary Activity Assay" column are herein incorporated by reference in their entireties, particularly with respect to the description of the respective activity assay described in the reference (see Methods section, for example) for assaying the corresponding biological activity set forth in the "Biological Activity" column of Table 1. The "Preferred Indication Y" column describes disease, disorders, and/or conditions that may be treated, prevented, diagnosed, or ameliorated by Therapeutic protein X or an albumin fusion protein of the invention comprising a Therapeutic protein X portion.

					The Control of the Minister W
Therapeutic Protein X	Exemplary	PCT/Patent Reference	Biological Activity	Exemplary Activity Assay	Freierred Indication
Alpha-1-antitrypsin (Alpha-1 proteinase; Alpha-1-trypsin inhibitor; Prolastin; API; API Inhale)	CAS-9041-92-3 LocusID:5265 LocusID:5299 NP_000286 NP_006211 XP_007481 XP_012372	WO8600337 EP103409-A EP155188 US5399684 US5736379 US6025161 US4839283 US4836197-A	Alpha-1-antitrypsin is an an enzyme inhibitor that belongs to the family of serpin serine protease inhibitors. The molecule inhibits the activity of trypsin and elastase.	Enzyme Inhibition asay: Gaillard MC, Kilroe-Smith TA. 1987 Determination of functional activity of alpha 1-protease inhibitor and alpha 2-macroglobulin in human plasma using elastase. J Clin Chem Clin Biochem. 25(3):167-72. Burnouf T, Constans J, Clerc A, Descamps J, Martinache L, Goudemand M. 1987 Biochemical and biological properties of an alpha 1-antitrypsin concentrate. Vox Sang;52(4):291-7	Emphysema; Infant Respiratory Distress Syndrome; Pulmonary Fibrosis; Respiratory Syncytial Virus Infections; Asthma; Cystic Fibrosis; Genitourinary Disorders; HIV Infections Treatment; Inflammatory Bowel Disorders; Skin Disorders; Viral Hepatitis; Alpha-1 Antitrypsin Deficiency; Adult Respiratory Distress Syndrome
Antihemophilic factor (Von Willebrand factor; Von Willebrand factor complex; HELIXATE- FS; HEMOFIL M; KOATE-DVI/HP; ALPHANATE; MONARC-M; HUMATE-P)	LocusID:7450 NP_000543 XP_006947	WO8606096 EP197592 WO9316709-A USS849536 US6008193 US5849702 US5238919	The glycoprotein encoded by this gene HIfunctions as both an antihemophilic factor carrier and a 1990 20(1):73) platelet-vessel wall mediator in Collagen bindi the blood coagulation system. It Willebrand fact is crucial to the hemostasis process. Mutations in this gene or deficiencies in this protein result in von Willebrand's disease.	Macroscopic platelet agglutination assay (Wright R. Ann Clin Lab Sci 1990 20(1):73). Collagen binding assay for von Willebrand factor (Favaloro EJ. Thromb Haemost 2000 83(1):127)	Hemophilia; Hemophilia A; von Willebrand disease
Antithrombin III (ATII; Antithrombin- heparin conjugate; ATH; aaATIII (Antithrombin III- modified); Atnativ; Anthrobin; Atenativ; Athimbin; Kybernin; Thrombhibin)	CAS-155319-91-8 CAS-52014-67-2 LocusID:462 NP_000479 XP_001452	WO9100291 EP568833 GB2116183	Serpin scrine protease that inhibits thrombin and other proteins involved in blood coagulation	Thrombin activity assay (Verheul et al., Blood 96:4216-4221, 2000)	Sepsis; Thrombosis; Unstable Angina Pectoris; Coagulation disorders; Respiratory Distress Syndrome; Control of blood clotting during coronary artery bypass surgery; Cancer (aaATIII)

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Reference	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
Ano-linoprotein (Ano	CAS-150287-52-8	WO8803166-A	ApoA1 promotes cholesterol	Cholesterol efflux from human	Atherosclerosis; Coronary
E: Apo A4: Apo A1;	LocusID:335	WO9307165-A	efflux from tissues to the liver for	efflux from tissues to the liver for fibroblasts can be directly measured	restenosis;
Apo B)	LocusID:338	US5408038-A.	excretion. ApoA1 is the major	in response to lipid reconstituted	Hypercnotesterotenna;
	LocusID:348	WO9107505-A	protein component of high	ApoA (J Biol Chem 1996 Oct	Hyperupideima; Kaposi s
	NP 000030	W09315198-A	density lipoprotein (HDL) in the	11;271(41):25145-51). The capacity	Sarcoma
	NP_000375	US5472858-A	plasma. ApoA1 is a cofactor for	of ApoB to participate in LDL	
	NP_000032	US5364793-A	lecithin cholesterolacyltransferase	clearance can be evaluated by	
	XP_006435	WO8702062-A	(LCAT), which is responsible for	measurements of ApoB binding to	
-	XP_002288	W09307165-A	the formation of most plasma	hepatic lipase (J Biol Chem, Vol.	
-	XP_008844	WO9856938-A1	cholesteryl esters. Defects in the	273, Issue 32, 20456-20462) and	
	1	US4943527-A	ApoA1 gene are associated with	lipoprotein lipase (J Biol Chem.	
			HDL deficiency and Tangier	1995 Apr 7;270(14):8081-6.). ApoE	
	•		disease. ApoB is the main	binding to its receptor can be	,
	•	•	apolipoprotein of chylomicrons	measured directly for example as	
•			and low density lipoproteins	illustrated for the liver ApoE	
-		-	(LDL). ApoB binds triglycerides	receptor (J Biol Chem 1986 Mar	
-	,	-	and clears LDL from circulation.	25;261(9):4256-67).	-
-			ApoE is a component of		
		,	lipoproteins and a ligand for low		
	-		density lipoprotein receptor.		,
			ApoE binds to a specific receptor		•
			on liver cells and peripheral cells.		
			ApoE is essential for the normal		
		٠	lipoprotein constituents. Defects		
		-	dysbetalipoproteinemia, or type		
-			III hyperlipoproteinemia (HLP		
		•	III), in which increased plasma		
	-	•	cholesterol and triglycerides are		-
			the consequence of impaired		
-	,		clearance of chylomicron and		
			V LOUD TOMINMENS:		

Therapeutic Protein X	Exemplary	PCT/Patent	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
		Reference			
Applagein	CAS-129037-76-9	WO9409036-A	Applaggin (Agkistrodon		Thrombosis; Stroke; Ischemic
(Agkistrodon piscivorus Genbank: A33990	Genbank:A33990	WO9008772-A	piscivorus piscivorus platelet		Heart Disorders
piscivorus (North		W09210575-A	aggregation inhibitor) is a	platelet serotonin release induced by	
American water		JP05255395-A	17,700-Da polypeptide dimer	ADP, gamma-thrombin, and	
moccasin snake).			which a potent inhibitor of	collagen. (Proc Natl Acad Sci U S A	
disulfide-linked Are-			platelet activation. Applaggin	1989 Oct;86(20):8050-4).	•
GIv-Asn-containing			blocks platelet aggregation		
dimeric polypeptide)			induced by ADP, collagen,		•
		-	thrombin, or arachidonic acid.		
٠		-	This inhibition is found to		
			correlate with inhibition of		
			thromboxane A2 generation and	•	•
	,		of dense granule release of		
	•	•	serotonin.		
Autocrine motility	LocusID:2821	WO\$707617-A	WO8707617-A Glucose phosphate isomerase	Cell motility assay on mouse CT-26 [Hemolytic anemia;	Hemolytic anemia;
factor (AMF:	NP 000166	WO9909049-A1	(neuroleukin); neurotrophic factor	(neuroleukin); neurotrophic factor cells (Sun et al., Proc. Natl. Acad. glucosephosphate isomerase	glucosephosphate isomerase
phosphoglucose	XP_012854		and lymphokine; bladder cancer	Sci. USA 96: 5412-5417, 1999; Lin deficiency; Hydrops fetalis	deficiency; Hydrops fetalis
isomerase; glucose			diagnostic.	et al., Mol. Cell. Endocrinol. 84:47-	•
phosphate isomerase;	-	-		54, 1992)	•
neuroleukin)		`			

Preferred Indication Y	Angioedema, Pancreatic Disorders; Reperfusion Injury; Transplant Rejection; Vascular	e ion incirci								-											,							
Exemplary Activity Assay		15;152(6):3199-209)															-								,			
Biological Activity	Activation of complement is an essential part of the mechanism of pathogenesis of a large number	of human diseases. C1-esterase inhibitor (C1-INH) concentrate	prepared from human plasma is	treatment of hereditary	angioneurotic edema. Recently,	C1-INH has been found to be consumed in severe inflammation	and has been shown to exert	beneficial effects in several	inflammatory conditions such as	human sepsis, post-operative	inyocardial dyslunction due to	capillary leakage syndrome after	bone marrow transplantation,	reperfusion injury after lung	transplantation, burn, and	cytotoxicity caused by IL-2	therapy in cancer. is a major	initional of two pro-	systems, the classical pathway of	complement and the contact	activation system. During the	activation of classical pathway,	C1-INH interacts with the	activated C1 and inhibits it.	Interaction of C1-INH with	activated C1 complex leads to the	dissociation of the C1q subunit	and Animation
PCT/Patent Reference	US5622930-A WO9106650-A	`									,	49,445					•							-	•			
Exemplary Identifier	CAS-80295-38-1 LocusID:710 NP_000053	XP_006339			-	•			-						•				-				_					
Therapeutic Protein X	lent	C1 inactivator; C1 [Inattivatore Umano]		9		-							-			-			•	-	•				•		•	

Therapeutic Protein X	Exemplary	PCT/Patent Reference	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
Coagulant Complex (Anti-Inhibitor					Control of spontaneous bleeding in hemophilia A and B: prevention of bleeding in
Coagulant Complex; FEIBA VH;					patients on Factor VIII inhibitors
ii	LocusID:1401 NP_000558 XP_001859	WO9221364-A WO9505394-A	Acute-phase serum protein that binds microbial polysaccharides and ligands on damaged cells,	Platelet activation (Simpson RM. Immunology 1982 47(1):193) Platelet aggregation (Cheryk LA. Vet	
-			activates the classical complement pathway	Immunol Immunopathol 1996 52:27). Increased production of IL-1	· .
·				macrophages (Galve-de Rochemonteix B. J Leukoc Biol	
	٠.			1993 53:439)	: :
EPO (Erythropoietin; Epoetin alfa; Epoetin	CAS-113427-24-0 CAS-122312-54-3	WO9902710-A1 WO8502610-A	Hormone that senses and regulates the level of oxygen in	Cell proliferation assay using a erythroleukemic cell line TF-1.	Anemia; Bleeding Disorders
beta; Gene-activated	LocusID:2056 NP 000790	WO8603520-A WO9206116-	the blood by modulating the	(Kitamura et al. 1989 J.Cell. Physiol. 140:323)	
Darbepoetin-alpha;	XP 011627	AW09206116-A	erythrocytes		
NESP; Epogen; Procrit;	I	US5985607-A	-		-
Eprex; Erypo; Espo; Epoimmun; EPOGIN;		EF 23.2034			
NEORECORMON;	•				
HEMOLINK; Dynepo; ARANESP)			-		

N V		âŝ		Sung.	III Footou	racioi											-						
Preferred Indication Y		Hemophilia B; bleeding;	iciency;	Christmas disease; bieeding	episodes in parients with	ractor VIII innibitor of Factor	>-																
Preferred		nophilia]	Factor LX deficiency;	istmas di	sodes in p	or VIII III	VII deficiency									•							
	_	-				Iac	II A								_								
y Assay		Factor IX clotting activity: Valder	R. et al., 2001 "Posttranslational	inant	myotube-synthesized human factor	·										-							
Exemplary Activity Assay		ng activi	"Posttran	modifications of recombinant	esized hu	IX" Blood 97: 130-138.											•						
xemplar	,	IX clotti	.l., 2001	cations o	be-synth(100d 97		*		•							• ,						
E		Factor	R. et a	modifi	myotu	m XI				-												S	
ity		13	tor that	s an	r IX is	rm by	s the	ins	and a	by one	In the	je,	activated factor IX activates factor	ugh	ions,	s, and	of this	gene, including point mutations,	canse	ich is a	der, also	called hemophilia B or Christmas	
Biological Activity		Coagulation factor IX is a	vitamin K-dependent factor that	circulates in the blood as an	inactive zymogen. Factor IX is	converted to an active form by	factor XIa, which excises the	activation peptide and thus	generates a heavy chain and a	ight chain held together by one	or more disulfide bonds. In the	blood coagulation cascade,	IX active	X to its active form through	interactions with Ca+2 ions,	membrane phospholipids, and	factor VIII. Alterations of this	point m	insertions and deletions, cause	factor IX deficiency, which is a	recessive X-linked disorder, also	lia B or (
Biologic	b	ation fac	K-depe	tes in the	e zymog	ted to an	XIa, whic	ion pepti	es a heav	nain held	e disulfic	oagulatie	ed factor	s active f	tions wit	ane phos	VIII. Alte	ncluding	ons and d	X defici	ve X-lin	hemophi	
	<u> </u>	Coagul	vitamin	circulat	inactive	conver	factor ?	activati	generat	light ch	or mor	blood	activate	X to its	interac	membr	factor	gene, i	insertic	factor I	recessi	called]	Jinong
PCT/Patent	Reference)5125-A	376-A	737-A1	2-A	260-A	71-A		ડ				-		•								
PCT/I	Refer	WO8505	WO8505376-A	W09747737-A1	EP162782-A	WO8400560-A	US4994371-A																
. A.	er.	95-5	`~~			•																•	
Fvamplary	Identifier	181054	LocusID:2158	NP 000124	XP_010270		-	•									•						
		CAS	Locu		Z dX								<u>.</u>		-	[27		·	-		· - ·		_
Deotoin	i nerapeune riotem A	Factor IX (Coagulation CAS-181054-95-5	nan):	nolex:	tor:	plasma thromboplastin	TĊ):	complex	(0)	a:	ĵ.,	SD:	BEBULIN: PROPLEX-		e SD:	BeneFIX: IMMUNINE							
410	abenne	r IX (Co	factor IX (human):	Factor IX Complex:	Christmas factor;	na throm	component (PTC):	prothrombin complex	concentrate (PCC):	Nonacos alpha:	MONONINE	AI.PHANINE-SD:	ULIN: P	T. KONYNE:	PROFILNINE SD;	FIX: IM						•	-
12.		Facto	factor	Facto	Chris	nlasn	comr	proth	COUC	Non	Š	AI.P	BEB	T: K	PRO	Bene	KHA	-		·			_

Identifier Reference	Reference WO8400560-A WO9323074-A			
rtion CAS-102786-61-8 ite LocusID:2155 II NP_000122 NP_062562 XP_007179 XP_007180 e;	O8400560-A O9323074-A			
iite LocusID:2155 II NP_000122 NP_062562 XP_007179 XP_007180 e;	09323074-A	Coagulation factor VII is a	Coagulation Assay using	Bleeding Disorders; Coronary
II NP_000122 US558 NP_062562 US558 XP_007179 US499 XP_007180 EP200 WO94; WO936		vitamin K-dependent factor	Prothrombin Clotting Time	Restenosis; Hemophilia A and
NP_062562 US558 XP_007179 US499 XP_007180 EP200 WO947 WO933	JS5997864-A	essential for hemostasis. This	(Belaaouaj AA et al., J. Biol. Chem. B; Liver Disorders;	B; Liver Disorders;
XP_007179 US4999 XP_007180 EP200 WO945 WO95 WO95 WO95 WO95 WO95 WO95 WO95 WO9	JS5580560-A	factor circulates in the blood in a	275: 27123-8, 2000; Diaz-Collier JA Thrombosis; Vascular	Thrombosis; Vascular
xP_007180 EP200 WO94; WO934	JS4994371-A	zymogen form, and is converted	et al., Thromb Haemost 71: 339-46, [Restenosis, Surgery-related	Restenosis; Surgery-related
e; W0937	EP200421-A		1994).	hemorrhagic episodes
w093(VO9427631-A	IXa, factor Xa, factor XIIa, or		-
MONOCLATE-P)	O9309804-A	thrombin by minor proteolysis.	•	
		Upon activation of the factor VII,		
		a heavy chain containing a	•	
		catalytic domain and a light chain		
		containing 2 EGF-like domains		-
	•	are generated, and two chains are		<i>:</i>
		held together by a disulfide bond.		
		In the presence of factor III and	•	
		calcium ions, the activated factor		
		then further activates the		-
		coagulation cascade by converting		
		factor IX to factor IXa and/or		
		factor X to factor Xa. Defects in		
		this gene can cause coagulopathy.		

Preferred Indication Y	Hemophilia A, Hemophilia; Surgery-related hemorrhagic enisodes										~			,								,	
Exemplary Activity Assay	Development of a simple chromogenic factor VIII assay for chinical use	Wagenvoord RJ, Hendrix HH,	Hemker HC. Haemostasis 1989:19(4):196-204.									_	•						•				
Biological Activity	This gene encodes coagulation factor VIII, which participates in	coagulation; factor VIII is a	cofactor for factor IXa which, in	phospholipids, converts factor X	to the activated form Xa. This	gene produces two alternatively	spinced danser press, manager pre	glycoprotein, isoform a, which	circulates in plasma and	associates with von Willebrand	factor in a noncovalent complex.	This protein undergoes multiple	cleavage events. Transcript	variant 2 encodes a putative small	protein, isoform b, which	consists primarily of the	phospholipid binding domain of	factor VIIIc. This binding domain	is essential for coagulant activity.	Defects in this gene results in	hemophilia A, a common	recessive X-linked coagulation	disorder.
PCT/Patent Reference	WO9621035-A2 WO9703195-A1	EP160457-A	EP160457-A	EP253455-A																,	·.		
Exemplary Identifier	CAS-139076-62-3 LocusID:2157	NF_000123 · XP_013124	l		•	•				•													
Therapeutic Protein X	or VIII;	Moroctocog alfa; Recombinant	tor;	Nordiate; Keracio; Kogenate: Kogenate	SF; Helixate;	Recombinate)	-					,						•				-	1

The grant of Destain V	Fyamnlary	PCT/Patent	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
The apenier Troining	Identifier	Reference			
Factor X	Locals ID: 2159	WO9204378-A	Encodes the vitamin K-dependent	Encodes the vitamin K-dependent FACTOR X ACTIVITY ASSAY.	Factor X deficiency; Stuart-
	NP 000495	WO9309804-A	coagulation factor X precursor of	coagulation factor X precursor of Van Wijk EM et al. A rapid manual Prower factor deficiency;	Prower factor deficiency;
	XP 007182	US4994371-A	the blood coagulation cascade.	chromogenic factor X assay. Thromb hemorrhage; menorrhagia;	hemorrhage; menorrhagia;
			This factor precursor is converted	Res 22, 681-686 (1981).	hematuria; hemarthrosis
,	-		to a mature two-chain form by		
			the excision of the tripeptide		
	-		RKR. Two chains of the factor		
			are held together by 1 or more	. ,	
			disulfide bonds; the light chain		,
-	•		contains 2 EGF-like domains,		
	-		while the heavy chain contains		
		-	the catalytic domain which is		
			structurally homologous to those		
			of the other hemostatic serine	•	
			proteases. The mature factor is		(
		•	activated by the cleavage of the	,	
			activation peptide by factor IXa		
			(in the intrinsic pathway), or by	-	
		•	factor VIIa (in the extrinsic		
			pathway). The activated factor		,
,			then converts prothrombin to		
		•	thrombin in the presence of factor		
			Va, Ca+2, and phospholipid		•
			during blood clotting. Mutations		
,		•	of this gene result in factor X		
	-		deficiency, a hemorrhagic		
			condition of variable severity.		

Exemplary Activity Assay Preferred Indication Y	AY.		Balogh I, Vamosi G, Muszbek L. wound healing; habitual	netic	say for the	delermination of blood coagulation	tactor XIII activity in plasma. Clin	Chem. 2000 Dec;46(12):1946-55.	•		,		-				-								-				,		
Exemplary	BLOOD COAG	Karpati L, Penl	Balogh I, Vamo	A modified, opi	photometric assay for the	determination o	tactor XIII act	Chem. 2000 De		,				٠		•								•					•		
Biological Activity	Coagulation factor XIII is the last					s. The	A subunits have catalytic	function, and the B subunits do	not have enzymatic activity and	may serve as a plasma carrier	molecules. Platelet factor XIII is	comprised only of 2 A subunits,	which are identical to those of	plasma origin. Upon activation	by the cleavage of the activation	peptide by thrombin and in the	presence of calcium ion, the	plasma factor XIII dissociates its	B subunits and yields the same	active enzyme, factor XIIIa, as	platelet factor XIII. This enzyme	acts as a transglutaminase to	catalyze the formation of gamma-	glutamyl-epsilon-lysine	crosslinking between fibrin	molecules, thus stabilizing the	fibrin clot. Factor XIII deficiency	is classified into two categories:	type I deficiency, characterized by	the lack of both the A and B	
PCT/Patent Reference	WO9116931-A	EP494702-A	US7425887-A	WO9102536-A	WO9918200-A					•			-				-	-		•	<i>y</i>										
Exemplary Identifier	LocusID:2162	LocusID:2163	LocusID:2164	LocusID:2165	NP_000120	NP_001985	XP_004467	XP_001350	1							•				• ,	-					•	,	-			_
Therapeutic Protein X	Factor XIII				•		-				•			,			-												•	•	

_							_																									_	_						_
13. 17 12 21 0 th	Preferred Indication Y	Tissue adhesion; thrombosis;	bleeding disorders; wounds;	thrombocytopenia;	dysfibrinogenemia;	hypofibrinogenemia:	afihrinogenemia, renai	amor mobalistic throws house.	annylondosis, unionicosis,	dysprothrombinemia							,	,				٠		,			•						÷.	-					
	Exemplary Activity Assay	Fibrinogen assay: Halbmayer WM,	fibringen is cleaved by thrombin Haushofer A. Schon R. Radek J.	Fischer M. Comparison of a new		fibringoen assay with the 3 most	mood fibring an accaye (functional	used Holmogen assays (unicuonal,	derived and nephelometric) in	Austrian laboratories in several	clinical populations and healthy	controls. Haemostasis 1995 May-	Jun:25(3):114-23. Tan V. Doyle CJ.					conditions affecting fibrinogen	coasulability Am J Clin Pathol.	1995 Oct. 104(4):455-62. Lawrie	AS, McDonald SJ, Purdy G, Mackie	IJ, Machin SJ. Prothrombin time	derived fibrinogen determination on	Sysmex CA-6000. J Clin Pathol.	1998 Jun;51(6):462-6. Aprotinin	assay: Cardigan RA, Mackie IJ,	Gippner-Steppert C, Jochum M,	Royston D, Gallimore MJ.	Determination of plasma aprotinin	levels by functional and	immunologic assays. Blood Coagul	Fibrinolysis, 2001 Jan;12(1):37-42.	Thrombin assay: Syed S, R[4]C	PD, Kulczycky M, Sheffield WP.	Potent antithrombin activity and	delayed clearance from the	circulation characterize recombinant	hirudin genetically fused to albumin.	Biood, 1997 May 1,89(9):3243-32.
	Biological Activity	Following vascular injury	fibrinogen is cleaved by thrombin	to form fibrin which is the most	ahundant component of blood	alote In addition various	Clots, ill addition, various	cleavage products of Horniogen	and fibrin regulate cell adhesion	and spreading, display	vasoconstrictor and chemotactic	activities and are mitopens for	several cell types Coagnilation	factor II is profeolyfically cleaved	to form thrombin in the first sten	of the cogoniation cascade which	of investigations of the	stemming of blood loss F2 also	stemming of order ress. 12 miles	vascular integrity			•											•				٠	
	PCT/Patent Reference	1196083907.A	W/O9523868_A1	WO9416085-A	WO0523868-A 1	11,006,020,00 A 1	WO9223000-M1	WO9529686-A1	US6083902-A	WO9523868-A1	WO9528946-A1	W/O9313208_A	1155502034-A	A-77774-A	A-107011821						-					-						•		-	•				
	Exemplary Tdentiffer	I countD-0042	LocusiD.2243	I ocusto.7366	1 00,000 TATO	LOCUSID.2147	NF 000499	NP_068657	NP_005132	NP 000500	NP_068656	NTD 000407	1/t-000 - INT						-					-												,			
•	Therapeutic Protein X	T. 1	Fibrinogen, unfolution,	aprotinin (riuman	Hormogen, numan			synthocytes; FAMs;	_										4														,		,				
•	:																	2	1																				

Inerapeune From A	Exemplary	PCT/Patent	Biological Activity	Exemplary Activity Assay	ricicii cu mulcanon i
	Identifier	Kererence	Ottlotes the moliferation and	Proliferation of murine NFS-60 cells	Chemoprofection:
G-CSF (Granulocyte C/	CAS-121181-53-1	WO8604506-A	Stimulates the proliferation and		
colony-stimulating C/	CAS-135968-09-1	EP220520-A	differentiation of the progenitor	Head Sel	Milianimatory disorders,
	CAS-130120-55-7	WO8604506-A	cells for granulocytes	U S A 1986; 83, pp5010-4)	Myelocylic Jeunellia,
	CAS-130120-54-6	WO8701132-A			Primary neutropenias (e.g.;
_	0 12 0210C1 3 V	TTS6050204-A			Kostmann syndrome) or
<u>. (</u>	4.2-1.34000-7-4-7	D-+67+60000			secondary neutropenia:
7	LocusID:1440				Designation of neutronenia:
Z	000750 P				rievelliton of mentiopenia,
	V 008227	•			Prevention and treatment of
				•	neutropenia in HIV-infected
Gran; GKANOCY IE;				,	patients: Infections associated
	-				with neutronenias:
Neutrogin; Neu-up;				•	Man noun openius,
•					Myelopyspiasia, Autominium disorders
-+				O.1. Ot. Daties A good. Ports	Done Morrow Disorders: Bone
GM-CSF (Granulocyte- ICA	CAS-99283-10-0	WO8805786	Regulates hematopoietic cell	Colony Stimulating Assay: 1 esta,	Bone Marrow Disorders, Done
	CAS-123774-72-1	WO8600639	differentiation, gene expression,	N.G., et al., "Assays for	marrow transplant;
	CAS-60154-12-3	WO8603225	growth	hematopoietic growth factors."	Chemoprotection; Hepatitis
Luch Cor. D.	7 7 137 16 7	1125301706		Balkwill FR (edt) Cytokines, A	C; HIV Infections; Lung
<u>;</u>	omeTD:1/437	7175545536	,	practical Approach, pp 229-44; IRL	Cancer; Malignant melanoma;
<u> </u>	000740		•	Press Oxford 1991.	Mycobacterium avium
	INF 000/49				complex: Mycoses: Myeloid
-₩	10/500-1				I onfomis: Meonatel
CSF/IL 3 fusion;	-				Leukeillia, ivedilatai
					Infections; Neutropenia; Oral
		-			mucositis; Prostate Cancer;
-	-				Stem Cell Mobilization;
	-				Vaccine Adjuvant: Venous
LEONOMAN,					Stasis Ulcers: Prevention of
					neutropenia. Acute
		-	•	•	myelogenous Jenkemia.
					It is not a printing and constant of [1]
			٠	•	Hematopoletic progenitor cen
	•				mobilization; Non-Hodgkin's
	-	-	٠		lymphoma; Acute
			-		lymphoblastic leukemia;
				,	Hodgkin's disease; Accelerated
,	-				myeloid recovery.
					Myciola Iccovery, Xenotraneniant rejection

מסט	Exemplary	PCT/Patent Reference	. Biological Activity	Exemplary Activity Assay	Freierred Indication x
TOT	131111	AND LOUNT			Exposine to Henstitis B
III IC (II captitie		•			Exposure to richaritis D
Hepanns 10 (nepanns			,		(HRsAp) or Henatitis C:
B Immine Globulin:			-		(2)
d minute discussion,			,		perinatal exposure of infants
Hepatitis C immune				-	Livith URV or HCV infected
Lohnlin UCVIG.					WILLIAM OF THE VILLAGOR
grobuini, ricy id,				-	mothers:: sexual or household
BAYHEP: NABI-HB:		•	•		4 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 -
(di) vino id vic					exposure to patient with acute
NABI-CIVACIN)					HBV or HCV

Therapeutic Protein X		PCT/Patent	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
	Identifier	Kererence			
Hepatocyte growth	LocusID:3082	JP03130091-A		Adams JC et al Production of scatter	Alopecia; Cancer;
factor (HGF; Scatter	Genbank:CAA34387	JP10070990-A	s	factor by ndk, a strain of epithelial	Chemoprotection; Cirrnosis;
factor: SF: HGF/SF)	,	W09323541-A	ıst-	cells, and inhibition of scatter factor	Haematological disorders,
	`		like phenotype in individual	activity by suramin: Journal of Cell	Kadioprotection
	-		0	Science 98: 385-94 (1991); Bhargava	
		•	Jo I	MM et al Purification,	
	•		tumor cells derived from	characterization and mechanism of	
,	٠		epithelial cells and may be	action of scatter factor from human	- ,,
	٠		involved also in processes of	placenta. Experientia Suppl. 59: 63-	
•	•	•	Wound healing and early	75 (1991); Coffer A et al	
			embryonic development. For	Purification and characterization of	
			some cell types including	biologically active scatter factor from	
-		-	keratinocytes and mammary	ras-transformed NIH-3T3	
			epithelial cells HGF is merely a	conditioned medium. Biochemical	
			motility factor. It is also an	Journal 278: 35-41 (1991); Dowrick	
	-	•	autocrine modulator that	PG et al Scatter factor affects major	•
,			influences the motility of the	changes in the cytoskeletal	
•			tent	organization of epithelial cells	
		,	mitogen for hepatocytes and also	Cytokine 3: 299-310 (1991);	
•			a morphogen (see: HGF,	Furlong RA et al Comparison of	
			hepatocyte growth factor). HGF	biological and immunochemical	
			binds to heparin and this may be	properties indicates that scatter factor	
			important for its activities in	and hepatocyte growth factor are	
			vivo. The actions of HGF are	indistinguishable. Journal of Cell	
•			inhibited by Suramin . HGF has	Science 100: 173-7 (1991); Gherardi	
	•		been shown to be an	E et al Purification of scatter factor,	
•			Angiogenesis factor in vivo. It	a fibroblast-derived basic protein that	
		,	induces cultured microvascular	modulates epithelial interactions and	
		-	endothelial cells to accumulate	movement. Proceedings of the	
-			and secrete significantly increased	and secrete significantly increased National Academy of Science (USA)	
			quantities of urokinase, an		
		-	enzyme associated with		
	-		development of an invasive		
	,		endothelial phenotype during		
			aligiogenesis, mor		

				1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Duoformod Indination V
Therapeutic Protein X	Exemplary	PCT/Patent	Biological Activity	Exemplary Activity Assay	r ference marcanon r
•	Identifier	Reference	, , , , , , , , , , , , , , , , , , ,		
Windin II onimalin.	CAS-138068-37-8	WO8504418-A	Hirudin is a potent anticoagulant Hirudin activity can be measured	Hirudin activity can be measured	Coronary restenosis; Deep
ringin (Lepindan,	3 15 200001 240	ED000655 A	which inhihits thrombin	nsing a platelet aggregation assay	Vein Thrombosis;
Desirudin; Keffudan;	CAS-120993-33-3	EL 200033-A		(Rlond Coagul Fibrinolysis 1996	Disseminated Intravascular
Revasc)	CAS-8001-2/-2	DE 20206274		Mar. 7(2):259-61)	Coagulation: Heparin-induced
	Genbank:AAA29195 WO920/8/4-A	WO920/8/4-A		IVIAL, 1(2):2019.	
	Genhank: A A A 01384	WO9201712-A			thrombocytopenia and
		EP340170-A		*	thrombosis syndrome;
	٠	ED241215 A			Myocardial infarction;
		DE 041210-0	,		Unstable Angina Pectoris:
٠		WO920/8/4-A			A
•		WO9201712-A		•	Anticoaguiant in addits
	•				suffering from acute coronary
•					syndrome; Thrombosis;
				:	Veinous Thrombosis

Preferred Indication Y	Acromegaly; Growth failure; Growth failure and endogenous growth hormone replacement; Growth hormone deficiency; Growth failure and growth retardation Prader- Willi syndrome in children 2 will syndrome in children 2 years or older; Growth deficiencies; Postmenopausal osteoporosis; burns; cachexia; nn, encer cachexia; dwarfism; metabolic disorders; obesity; renal failure; Turner's Syndrome; fibromyalgia; fracture treatment; frailty fracture treatment; frailty
Exemplary Activity Assay	Plays an important role in growth Ba/F3-hCHR proliferation assay, a control; binds 2 GHR molecules human growth hormone. J Clin human growth hormone. J Clin Bndocrinol Metab 2000 Nov;85(11):4274-9 Plasma growth hormone (GH) immunoassay and tibial bioassay, Appl Physiol 2000 Dec;89(6):2174-8 Growth hormone (hGH) receptor mediated cell mediated proliferation, Growth Horm IGF Res 2000 Oct;10(5):248-55 International standard for growth hormone, Horm Res 1999;51 Suppl 1:7-12
Biological Activity	Plays an important role in growth control; binds 2 GHR molecules and induces signal transduction through receptor dimerization
PCT/Patent Reference	WO9418227-A WO905185-A WO906185-A WO906185-A WO90604788-A WO9013579-A US6194176-A US6194176-A US6194176-A US6194176-A WO9605804 US6955346 US6913478 WO9605804 WO9605804 WO9605804 WO9605804 US5580723 US580723 US5580723 US5580723 US5580723 US5580723 US5580723 US5580723 US5580723
Exemplary Identifier	CAS. CAS. CAS. CAS. CAS. CAS. CAS. CAS.
Therapeutic Protein X	Human growth hormone (Pegvisamont; Somatrem; Somatropin; TROVERT; PROTROPIN; BIOTROPIN; HUMATROPE; NUTROPIN; NORDITROPIN; SAIZEN; SEROSTIM) SAIZEN; SEROSTIM)

Therapeutic Protein X	Exemplary	PCT/Patent	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
	Identifier	Reference		-	4
Insulin (Human insulin-ICAS-11061-68-0	CAS-11061-68-0	WO200040613-	Insulin is a heterodimeric	Insulin activity may be assayed in	Hyperglycemia; Diabetes
Insulin general: Insulin CAS-116094-23-6	CAS-116094-73-6	A1	polypeptide hormone involved in	polypeptide hormone involved in vitro using a [3-H]-glucose uptake	mellitus; Type I diabetes and
Clouding Inavilia liento: CAS-133107-64-9	CAS-133107-64-9	FP1773-A	carbohydrate metabolism. After	assay. (J Biol Chem 1999 Oct 22;	type 2 diabetes
Clargine, moduli napro,	CAS-155187-04 5	ED55047-A	removal of the preciusor signal	274(43):30864-30873).	
	CAS-10035/-52-1	110401440	contide accinedly to neet		
lyspro; LY 275585;	Locus1D:3630	US4451/40-A	pepuae, promsum is post-		
diarginylinsulin; Des-	NP_000198	US4430266-A	translationally cleaved into two	•	
B26-B30-insulin-B25-	XP 006400	US4624926-A	chains (peptide A and peptide B)		,
amide: Insulin detemir;	1	US5077204-A	that are covalently linked via two		
LABI: NOVOLIN;		US5840542-A	disulfide bonds. Binding of this		-
NOVÓRAPID;		US6110707-A	mature form of insulin to the		•
HUMULIN		WO9200322-A	(insulin receptor (INSR)		-
NOVOMIX 30;	-		stimulates glucose uptake.		
VELOSULIN;					
NOVOLOG; LANTUS;					
LETIN; HUMALOG;					
MACRULIN;			•		·
EXUBRA; INSUMAN;		-			
ORALIN; ORALGEN;	-				
HUMAHALE;			•		
HUMAHALIN)					

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Reference	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
Interferon alfa	CAS-74899-72-2	EP32134	Interferon alpha belongs to the	Anti-viral assay: Rubinstein S,	Hepatitis C; oncology uses;
	CAS-76543-88-9	WO9419373-A	type I Interferon family of	Familletti PC, Pestka S. (1981)	cancer; hepatitis; human
	CAS-99210-65-8	WO9201055	functionally related cytokines that Convenient assay for interferons.	Convenient assay for interferons. J.	papilloma virus; iloromyaigia;
alfa-n1; Interferon alfa-	LocusID:3440	US5602232	conter a range of cellular	Virol. 5/(2):/55-8; Anti-	Sjogren's syndroline, nany cen
alpha-	NP_000596	US6069133	responses including antiviral,	proliferation assay: Gao Y, et al	Jeukemia; cinonic
	XP_011801	WO8302461	antiproliferative, antifumor and	(1999) Sensitivity of an epstern-barr	myelogeonus leukenna,
interferon alfa-2b; (CAS-9008-11-1	US6069133	immunomodulatory activities.	virus-positive tumor line, Daudi, to	AIDS-related naposi s
Interferon alfacon-1; (CAS-118390-30-0	US4569908	•	alpha interferon correlates with	sarcoma; chronic hepatitis B;
nterferon consensus;	LocusID:3439	US4758428		expression of a GC-rich viral	malignant melanoma; non-
YM 643; CIFN;	NP_076918	,		transcript. Mol Cell Biol.	Hodgkin's lymphoma;
	l		•	(19(11):7305-13.	external condylomata
consensus; recombinant	-				acuminata; HIV infection;
methionyl consensus	-			.,	small cell lung cancer;
interferon; recombinant					hematological malignancies;
consensus interferon;					herpes simplex virus
269: RO	•				infections; multiple sclerosis;
253036; RO 258310;		•			viral hemmorhagic fevers;
INTRON A; PEG-		•			solid tumors; renal cancer;
NTRON, OIF,	,				bone marrow disorders; bone
OMNIFERON; PEG-					disorders; bladder cancer;
OMNIFERON;					gastric cancer; Hepatitis D;
VELDONA; PEG-	•		, -		multiple myeloma; type I
REBETRON;					diabetes mellitus; viral
ROFERON A;					infections; Cutaneous 1-cell
WELLFERON;	-	-			lymphoma; Cervical
ALFERON N/LDO;					dysplasia; Chronic tatigue
REBETRON;				•	syndrome; Renal cancer
ALTEMOL;					
VIRAFERONPEG;					
PEGASYS,				-	
VIKAFEKON;					
VIKAFON;					
NFERGEN:			·		
MEAREX: OBAGEN)					-

Therapeutic Protein X	Exemplary Identifier	PCT/Patent Reference	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
VIG (Intravenous			Regulates hematopoietic cell		Immune deficiencies;
mmune Globulin;			differentiation, gene expression,	• •	agammaglobulinemia;
VENOGLOBULIN-S;	c		Blown		immunodeficient states and
POLYGAM:					bacterial infections; Kawasaki
GAMMAR-P;					Syndrome; Hepatitis A;
GAMMAGARD S/D;	-	•			measles varicella; rubella;
IVEEGAM; BAYGAN;					immunoglobulm deficiency;
SANDOGLOBOLIIN;				,	purpura; primary humoral
					immunodeficiency states;
,					bone marrow transplantation;
					pediatric HIV infection;
					Guillain-Barre syndrome;
	•				chronic inflammatory
			,		demyelinating
					polylleuropauly, inutiliocal
	•				neuropaniy, ucimiatonnyosins,
					amyou opine lateral scierosis;
	•				Inclusion-body inyositis;
	•				Lainbeit-Eaton Inyasuicine
	,	-	-		syndrome; Kasmussen
				, t	syndrome, west syndrome, intractable childhood enilensy:
		•			Tennox-Gastant syndrome:
					polymyositis; relapsing-
	ē	-			remitting multiple sclerosis;
		-	-		optic neuritis; stiff-man
•					syndrome; paraneuplastic
					cerebellar degeneration;
	•		,		paraneoplastic
			-		encephalomyelitis and sensory
					neuropathy; systemic
-					vasculitis; myelopathy
				•	associated with human T-cell
	_				lymphotrophic virus-1
					miconon.

Preferred Indication Y	Cytomegalovirus disease	
Exemplary Activity Assay		Neurite outgrowth assay, Neurosci Lett 2001 Mar 30;301(2):83-6 Cell adhesion assay, CAFCA, Centrifugal Assay for Fluorescence- based Cell Adhesion, Cancer Res 2001 Jan 1;61(1):339-47 Cell migration assay, Biochem Biophys Res Commun 2000 Nov 30;278(3):614-20
Biological Activity		Basement membrane protein; cell adhesion, differentiation, migration, signaling, neurite outgrowth and metastasis
PCT/Patent Reference		W09506660 US5658789-A W08901493-A W09811217-A2 W09511972-A W09111462-A W09111462-A W09919348-A1 W09919348-A1 W09919348-A1 W0991066730- A2 US7267564-A W09610646-A1 W0200066731- A2 US5658789-A W0200058473- A2
Exemplary Identifier		LocusID:3907 LocusID:3908 LocusID:3908 LocusID:3909 LocusID:3910 LocusID:3911 LocusID:3913 LocusID:3913 LocusID:3913 LocusID:3914 LocusID:3913 LocusID:3913 LocusID:3913 LocusID:3913 NP 000218 NP 002281 NP 002281 NP 002283 NP 002283 NP 002283 NP 002283 NP 002283 NP 002284 NP 006050 XP 011387 XP 004301 XP 001716 XP 001716 XP 002204 XP 002203 XP 002203 XP 002203 XP 002203
Therapeutic Protein X	IVIG-CMV (Cytomegalovirus immune globulin intravenous (human); CMV IVIG;	

Therapeutic Protein X	Exemplary	PCT/Patent	Biological Activity	Exemplary Activity Assay	Preferred Indication Y
-	Identifier	Reference			
MCP/MCAF	LocusID:6347	US5714578-A	JS5714578-A Chemotactic factor for	Transendothelial lymphocyte	Cancer; Chemoprotection;
(Monocyte Chemotactic LocusID:6355	LocusID:6355	US7330446-A	monocytes; chemokine involved	monocytes; chemokine involved chemotaxis assay: Carr, M.W., et	Wounds
Protein; Monocyte		US6090795-A	in recruiting leukocytes during	al., Proc. Natl. Acad. Sci. USA,	
		US7304234-A	inflammation; attracts	vol. 91, pp. 3652-3656 (April	
		US5571713-A	macrophages during	1994).	
		US5605671-A	inflammation and metastasis	-	
	008415	W09725427-A1			
		EP906954-A1			
,	012649	WO9912968-A2			
		WO9509232-A			
	-	EP488900-A			
		WO9504158-A			
	-	WO9509232-A			

M-CSF (Macrophage CA colony-stimulating Loc factor; CSF-1; Cilmostim; Macstim) XP	T 3	Defenonce			
Z Z Z Z	Identiller	Meiel elice			
<u> </u>	CAS-148637-05-2	US5171675-A	owth of	M-CSF can be assayed in a Colony	Cancer, Hypercholesterolemia
ŻŻ	LocusID: 1435	US4929700-A		formation assay by the development	
_	NP_000748	US5573930-A	on agar	01 colonies containing macrophages (
	0021200	US36/2343-A HS5681719-A	curules, injudities the profile of Nov.2(6):356-67). M-CSF is also	Nov:2(6):356-67). M-CSF is also	
		T105647562 A	homotonoietic etem celle into	detected in specific Rioassays with	
		US2043303-A		cells lines that depend in their	
		11S6117422-A		growth on the presence of M-CSF or	
		T1S6103224-A	nocytes. In	that respond to this factor, for	
		TIS6156300-A	combination with another colony	example, BAC1.2F5; BaF3;	
		US6146851-A	stimulating factor, GM-CSF, one	GNFS-60; J774. An alternative and	
			observes the phenomenon of	observes the phenomenon of entirely different detection method is	
•			synergistic suppression, i. e., the	RT-PCR quantitation of cytokines.	
		•	combination of these two factors		
	-	•	leads to a partial suppression of		•
		-	the generation of macrophage-		
-			containing cell colonies. M-CSF		
			is a specific factor in that the	•	
			proliferation inducing activity is	-	
			more or less restricted to the		-
			macrophage lineage. M-CSF also		
		<u></u>	is a potent stimulator of	2	
			functional activities of		c.
			monocytes. In normal human		
			macrophages M-CSF induces		
			antibody-dependent cellular		
		•	cytotoxicity. In monocytes and		
			macrophages M-CSF induces the		
	•		synthesis of IL1, G-CSF, IFN,		
			TNF, plasminogen activator,		
 			thromboplastin, prostaglandins and thromboxanes.		!
Ge	Genbank:CAC20427	W09931233-A1		Transendothelial lymphocyte chemotaxis assay: Carr, M.W., et	Wound healing
				al., Proc. Natl. Acad. Sci. USA,	
	-	•		1004)	

Kelerence
ļ
WO9915904-A1 WO200062065-
A1 W09222316-A
these conserved motifs. OPN is involved in a range of biological
activities including developmental processes,
healing, immunological responses, tumorigenesis, bone
resorption, and calcification.
WO9302192-A
WO9504158-A chemokine with strong anti- US5248666-A angiogenic properties.
W-7600
•

Protein C is a serine protease involved in coagulation and fibrinolysis. Coagulation factor II is proteolytically cleaved to four thrombin in the first step of the coagulation cascade, which
Coagulation factor II is proteolytically cleaved to form thrombin in the first step of the coaculation cascade, which
Coag prote thro
COS
ultimately results in the
stemming of blood loss. F2 also plays a role in maintaining
yascular integrity.
•
ı

PCT/US01/12009

Preferred Indication Y		
Exemplary Activity Assay	BchE activity assay "Differential inhibition of human serum cholinesterase with fluoride: recognition of two new phenotypes." Nature 191: 496-498, 1961. "A rare genetically determined variant of pseudocholinesterase in two German families with high plasma enzyme activity." Europ. J. Biochem. 99: 65-69, 1979. "Genetic analysis of a Japanese patient with butyrylcholinesterase deficiency." Ann. Hum. Genet. 61:491-496, 1997.	cell adhesion assay. "Cell adhesion to fibronectin and tenascin: quantitative measurements of initial binding and subsequent strengthening response." J Cell Biol. 1989 Oct; 109(4 Pt 1):1795-805.; "Tenascin interferes with fibronectin action." Cell. 1988 May 6;53(3):383-90. neurite growth in vitro. "Tenascin is accumulated along developing peripheral nerves and allows neurite outgrowth in vitro." Development. 1990 Oct; 110(2):401-15.
Biological Activity	Also known as butyrylcholinesterase/pseuocholin esterase E1(CHE1). Human cholinesterase with fluoride tissues have two distinct cholinesterase activities: acetylcholinesterase and butyrylcholinesterase functions in the transmission of nerve impulses, whereas the transmission of nerve impulses, whereas the transmission of nerve impulses, whereas the physiological function of butyrylcholinesterase remains unknown. An atypical form of butyrylcholinesterase or the absence of its activity leads to prolonged apnea following administration of the muscle relaxant suxamethonium. The widespread expression of CHE1 in early differentiation suggests development-related functions for this protein.	is (TN) are a family lar matrix proteins. ce expressed in test at different times ronic development ent in adult tissues. Sected predominantly il nervous system of os and likely central nervous ed in many tumors.
PCT/Patent Reference	WO9107483-A WO9523158-A US6001625-A US5695750-A	WO9628550-A1 WO9608513-A1 US5681931-A US5635360-A WO9222319-A WO9608513-A1 US5681931-A US5635360-A US5635360-A
Exemplary Identifier	LocusID:590 LocusID:1110 NP_000046 XP_003134	LocusID:7143 LocusID:7146 LocusID:7148 NP_003276 NP_009047 XP_001730 XP_004201
Therapeutic Protein X	Serum Cholinesterase	Tenascin

Preferred Indication V	Tetanus ·	Atherosclerosis; Vascular Restenosis; Cancer; Cardiovascular Disorders; Malignant Melanoma; Clotting disorders; Transplantation.
Exemplary Activity Assay		Individual functions of the molecule are assayed separately. The cell adhesion function is assayed using scell adhesion assay (Feinberg and Vogelstein, 1983; Anal. Biochem. 132 pp6-10); PAI binding using a solid phase binding assay (Seiffert & Loskutoff, 1991; J. Biol. Chem. 266 pp2824-2830)
Biological Activity		Binds to serpin serine protease inhibitors such as PAI, mediates cell-to-substrate adhesion, inhibits the cytolytic action of the terminal complement cascade in vitro and inhibits inactivation of thrombin by antithrombin, thereby regulating coagulation.
PCT/Patent Reference		US514582-A US6140072-A WO9213075-A
Exemplary Identifier		LocusID:7448 NP_000629 XP_008484
Therapeutic Protein X	Tetanus IG (Tetanus Immune Globulin; TIG; BAYTET)	-

In preferred embodiments, the albumin fusion proteins of the invention are capable of a therapeutic activity and/or biologic activity corresponding to the therapeutic activity and/or biologic activity of the Therapeutic protein corresponding to the Therapeutic protein portion of the albumin fusion protein listed in the corresponding row of Table 1. (See, e.g., the "Biological Activity" and "Therapeutic Protein X"columns of Table 1.) In further preferred embodiments, the therapeutically active protein portions of the albumin fusion proteins of the invention are fragments or variants of the reference sequence cited in the "Exemplary Identifier" column of Table 1, and are capable of the therapeutic activity and/or biologic activity of the corresponding Therapeutic protein disclosed in "Biological Activity" column of Table 1.

Polypeptide and Polynucleotide Fragments and Variants

Fragments

5

10

15

20

25

30

35

The present invention is further directed to fragments of the Therapeutic proteins described in Table 1, albumin proteins, and/or albumin fusion proteins of the invention.

Even if deletion of one or more amino acids from the N-terminus of a protein results in modification or loss of one or more biological functions of the Therapeutic protein, albumin protein, and/or albumin fusion protein, other Therapeutic activities and/or functional activities (e.g., biological activities, ability to multimerize, ability to bind a ligand) may still be retained. For example, the ability of polypeptides with N-terminal deletions to induce and/or bind to antibodies which recognize the complete or mature forms of the polypeptides generally will be retained when less than the majority of the residues of the complete polypeptide are removed from the N-terminus. Whether a particular polypeptide lacking N-terminal residues of a complete polypeptide retains such immunologic activities can readily be determined by routine methods described herein and otherwise known in the art. It is not unlikely that a mutein with a large number of deleted N-terminal amino acid residues may retain some biological or immunogenic activities. In fact, peptides composed of as few as six amino acid residues may often evoke an immune response.

Accordingly, fragments of a Therapeutic protein corresponding to a Therapeutic protein portion of an albumin fusion protein of the invention, include the full length protein as well as polypeptides having one or more residues deleted from the amino terminus of the amino acid sequence of the reference polypeptide (e.g., a Therapeutic protein as disclosed in Table 1). In particular, N-terminal deletions may be described by the general formula m-q, where q is a whole integer representing the total number of amino acid residues in a reference polypeptide (e.g., a Therapeutic protein referred to in Table 1), and m is defined as any integer ranging from 2 to q-6. Polynucleotides encoding these polypeptides are also

encompassed by the invention.

5

· 10

15

20

25

30

35

In addition, fragments of serum albumin polypeptides corresponding to an albumin protein portion of an albumin fusion protein of the invention, include the full length protein as well as polypeptides having one or more residues deleted from the amino terminus of the amino acid sequence of the reference polypeptide (i.e., serum albumin). In particular, N-terminal deletions may be described by the general formula m-585, where 585 is a whole integer representing the total number of amino acid residues in serum albumin (SEQ ID NO:18), and m is defined as any integer ranging from 2 to 579. Polynucleotides encoding these polypeptides are also encompassed by the invention.

Moreover, fragments of albumin fusion proteins of the invention, include the full length albumin fusion protein as well as polypeptides having one or more residues deleted from the amino terminus of the albumin fusion protein. In particular, N-terminal deletions may be described by the general formula m-q, where q is a whole integer representing the total number of amino acid residues in the albumin fusion protein, and m is defined as any integer ranging from 2 to q-6. Polynucleotides encoding these polypeptides are also encompassed by the invention.

Also as mentioned above, even if deletion of one or more amino acids from the N-terminus or C-terminus of a reference polypeptide (e.g., a Therapeutic protein and/or serum albumin protein) results in modification or loss of one or more biological functions of the protein, other functional activities (e.g., biological activities, ability to multimerize, ability to bind a ligand) and/or Therapeutic activities may still be retained. For example the ability of polypeptides with C-terminal deletions to induce and/or bind to antibodies which recognize the complete or mature forms of the polypeptide generally will be retained when less than the majority of the residues of the complete or mature polypeptide are removed from the C-terminus. Whether a particular polypeptide lacking the N-terminal and/or C-terminal residues of a reference polypeptide retains Therapeutic activity can readily be determined by routine methods described herein and/or otherwise known in the art.

The present invention further provides polypeptides having one or more residues deleted from the carboxy terminus of the amino acid sequence of a Therapeutic protein corresponding to a Therapeutic protein portion of an albumin fusion protein of the invention (e.g., a Therapeutic protein referred to in Table 1). In particular, C-terminal deletions may be described by the general formula 1-n, where n is any whole integer ranging from 6 to q-1, and where q is a whole integer representing the total number of amino acid residues in a reference polypeptide (e.g., a Therapeutic protein referred to in Table 1). Polynucleotides encoding these polypeptides are also encompassed by the invention.

In addition, the present invention provides polypeptides having one or more residues deleted from the carboxy terminus of the amino acid sequence of an albumin protein

corresponding to an albumin protein portion of an albumin fusion protein of the invention (e.g., serum albumin). In particular, C-terminal deletions may be described by the general formula 1-n, where n is any whole integer ranging from 6 to 584, where 584 is the whole integer representing the total number of amino acid residues in serum albumin (SEQ ID NO:18) minus 1. Polynucleotides encoding these polypeptides are also encompassed by the invention.

Moreover, the present invention provides polypeptides having one or more residues deleted from the carboxy terminus of an albumin fusion protein of the invention. In particular, C-terminal deletions may be described by the general formula 1-n, where n is any whole integer ranging from 6 to q-1, and where q is a whole integer representing the total number of amino acid residues in an albumin fusion protein of the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

In addition, any of the above described N- or C-terminal deletions can be combined to produce a N- and C-terminal deleted reference polypeptide. The invention also provides polypeptides having one or more amino acids deleted from both the amino and the carboxyl termini, which may be described generally as having residues m-n of a reference polypeptide (e.g., a Therapeutic protein referred to in Table 1, or serum albumin (e.g., SEQ ID NO:18), or an albumin fusion protein of the invention) where n and m are integers as described above. Polynucleotides encoding these polypeptides are also encompassed by the invention.

The present application is also directed to proteins containing polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to a reference polypeptide sequence (e.g., a Therapeutic protein, serum albumin protein or an albumin fusion protein of the invention) set forth herein, or fragments thereof. In preferred embodiments, the application is directed to proteins comprising polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to reference polypeptides having the amino acid sequence of N- and C-terminal deletions as described above. Polynucleotides encoding these polypeptides are also encompassed by the invention.

Preferred polypeptide fragments of the invention are fragments comprising, or alternatively, consisting of, an amino acid sequence that displays a Therapeutic activity and/or functional activity (e.g. biological activity) of the polypeptide sequence of the Therapeutic protein or serum albumin protein of which the amino acid sequence is a fragment.

Other preferred polypeptide fragments are biologically active fragments. Biologically active fragments are those exhibiting activity similar, but not necessarily identical, to an activity of the polypeptide of the present invention. The biological activity of the fragments may include an improved desired activity, or a decreased undesirable activity.

Variants

5

10

15

20

25

30

35

"Variant" refers to a polynucleotide or nucleic acid differing from a reference nucleic acid or polypeptide, but retaining essential properties thereof. Generally, variants are overall closely similar, and, in many regions, identical to the reference nucleic acid or polypeptide.

5

10

15

20

25

30

35

As used herein, "variant", refers to a Therapeutic protein portion of an albumin fusion protein of the invention, albumin portion of an albumin fusion protein of the invention, or albumin fusion protein differing in sequence from a Therapeutic protein (e.g. see "therapeutic" column of Table 1), albumin protein, and/or albumin fusion protein of the invention, respectively, but retaining at least one functional and/or therapeutic property thereof (e.g., a therapeutic activity and/or biological activity as disclosed in the "Biological Activity" column of Table 1) as described elsewhere herein or otherwise known in the art. Generally, variants are overall very similar, and, in many regions, identical to the amino acid sequence of the Therapeutic protein corresponding to a Therapeutic protein portion of an albumin fusion protein of the invention, albumin protein corresponding to an albumin protein portion of an albumin fusion protein of the invention, and/or albumin fusion protein of the invention. Nucleic acids encoding these variants are also encompassed by the invention.

The present invention is also directed to proteins which comprise, or alternatively consist of, an amino acid sequence which is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100%, identical to, for example, the amino acid sequence of a Therapeutic protein corresponding to a Therapeutic protein portion of an albumin fusion protein of the invention (e.g., an amino acid sequence disclosed in the "Exemplary Identifier" column of Table 1, or fragments or variants thereof), albumin proteins (e.g., SEQ ID NO:18 or fragments or variants thereof) corresponding to an albumin protein portion of an albumin fusion protein of the invention, and/or albumin fusion proteins of the invention. Fragments of these polypeptides are also provided (e.g., those fragments described herein). Further polypeptides encompassed by the invention are polypeptides encoded by polynucleotides which hybridize to the complement of a nucleic acid molecule encoding an amino acid sequence of the invention under stringent hybridization conditions (e.g., hybridization to filter bound DNA in 6X Sodium chloride/Sodium citrate (SSC) at about 45 degrees Celsius, followed by one or more washes in 0.2X SSC, 0.1% SDS at about 50 - 65 degrees Celsius), under highly stringent conditions (e.g., hybridization to filter bound DNA in 6X sodium chloride/Sodium citrate (SSC) at about 45 degrees Celsius, followed by one or more washes in 0.1X SSC, 0.2% SDS at about 68 degrees Celsius), or under other stringent hybridization conditions which are known to those of skill in the art (see, for example, Ausubel, F.M. et al., eds., 1989 Current protocol in Molecular Biology, Green publishing associates, Inc., and John Wiley & Sons Inc., New York, at pages 6.3.1 - 6.3.6 and 2.10.3). Polynucleotides encoding these polypeptides are also encompassed by the invention.

By a polypeptide having an amino acid sequence at least, for example, 95% "identical"

to a query amino acid sequence of the present invention, it is intended that the amino acid sequence of the subject polypeptide is identical to the query sequence except that the subject polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the query amino acid sequence. In other words, to obtain a polypeptide having an amino acid sequence at least 95% identical to a query amino acid sequence, up to 5% of the amino acid residues in the subject sequence may be inserted, deleted, or substituted with another amino acid. These alterations of the reference sequence may occur at the amino- or carboxy-terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.

As a practical matter, whether any particular polypeptide is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to, for instance, the amino acid sequence of an albumin fusion protein of the invention or a fragment thereof (such as the Therapeutic protein portion of the albumin fusion protein or the albumin portion of the albumin fusion protein), can be determined conventionally using known computer programs. A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci.6:237-245 (1990)). In a sequence alignment the query and subject sequences are either both nucleotide sequences or both amino acid sequences. The result of said global sequence alignment is expressed as percent identity. Preferred parameters used in a FASTDB amino acid alignment are: Matrix=PAM 0, k-tuple=2, Mismatch Penalty=1, Joining Penalty=20, Randomization Group Length=0, Cutoff Score=1, Window Size=sequence length, Gap Penalty=5, Gap Size Penalty=0.05, Window Size=500 or the length of the subject amino acid sequence, whichever is shorter.

If the subject sequence is shorter than the query sequence due to N- or C-terminal deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for N- and C-terminal truncations of the subject sequence when calculating global percent identity. For subject sequences truncated at the N- and C-termini, relative to the query sequence, the percent identity is corrected by calculating the number of residues of the query sequence that are N- and C-terminal of the subject sequence, which are not matched/aligned with a corresponding subject residue, as a percent of the total bases of the query sequence. Whether a residue is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This final percent identity score is what is used for the purposes of the present invention. Only residues

to the N- and C-termini of the subject sequence, which are not matched/aligned with the query sequence, are considered for the purposes of manually adjusting the percent identity score. That is, only query residue positions outside the farthest N- and C- terminal residues of the subject sequence.

5 .

10

15

20

25

30

35

For example, a 90 amino acid residue subject sequence is aligned with a 100 residue query sequence to determine percent identity. The deletion occurs at the N-terminus of the subject sequence and therefore, the FASTDB alignment does not show a matching/alignment of the first 10 residues at the N-terminus. The 10 unpaired residues represent 10% of the sequence (number of residues at the N- and C- termini not matched/total number of residues in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 residues were perfectly matched the final percent identity would be 90%. In another example, a 90 residue subject sequence is compared with a 100 residue query sequence. This time the deletions are internal deletions so there are no residues at the N- or C-termini of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only residue positions outside the N- and C-terminal ends of the subject sequence, as displayed in the FASTDB alignment, which are not matched/aligned with the query sequence are manually corrected for. No other manual corrections are to made for the purposes of the present invention.

The variant will usually have at least 75 % (preferably at least about 80%, 90%, 95% or 99%) sequence identity with a length of normal HA or Therapeutic protein which is the same length as the variant. Homology or identity at the nucleotide or amino acid sequence level is determined by BLAST (Basic Local Alignment Search Tool) analysis using the algorithm employed by the programs blastp, blastn, blastx, tblastn and tblastx (Karlin *et al.*, Proc. Natl. Acad. Sci. USA 87: 2264-2268 (1990) and Altschul, J. Mol. Evol. 36: 290-300 (1993), fully incorporated by reference) which are tailored for sequence similarity searching.

The approach used by the BLAST program is to first consider similar segments between a query sequence and a database sequence, then to evaluate the statistical significance of all matches that are identified and finally to summarize only those matches which satisfy a preselected threshold of significance. For a discussion of basic issues in similarity searching of sequence databases, see Altschul et al., (Nature Genetics 6: 119-129 (1994)) which is fully incorporated by reference. The search parameters for histogram, descriptions, alignments, expect (i.e., the statistical significance threshold for reporting matches against database sequences), cutoff, matrix and filter are at the default settings. The default scoring matrix used by blastp, blastx, tblastn, and tblastx is the BLOSUM62 matrix (Henikoff et al., Proc. Natl. Acad. Sci. USA 89: 10915-10919 (1992), fully incorporated by reference). For blastn, the scoring matrix is set by the ratios of M (i.e., the reward score for a pair of matching residues)

to N (i.e., the penalty score for mismatching residues), wherein the default values for M and N are 5 and -4, respectively. Four blastn parameters may be adjusted as follows: Q=10 (gap creation penalty); R=10 (gap extension penalty); wink=1 (generates word hits at every winkth position along the query); and gapw=16 (sets the window width within which gapped alignments are generated). The equivalent Blastp parameter settings were Q=9; R=2; wink=1; and gapw=32. A Bestfit comparison between sequences, available in the GCG package version 10.0, uses DNA parameters GAP=50 (gap creation penalty) and LEN=3 (gap extension penalty) and the equivalent settings in protein comparisons are GAP=8 and LEN=2.

5

10

15

20

25

30

35

The polynucleotide variants of the invention may contain alterations in the coding regions, non-coding regions, or both. Especially preferred are polynucleotide variants containing alterations which produce silent substitutions, additions, or deletions, but do not alter the properties or activities of the encoded polypeptide. Nucleotide variants produced by silent substitutions due to the degeneracy of the genetic code are preferred. Moreover, polypeptide variants in which less than 50, less than 40, less than 30, less than 20, less than 10, or 5-50, 5-25, 5-10, 1-5, or 1-2 amino acids are substituted, deleted, or added in any combination are also preferred. Polynucleotide variants can be produced for a variety of reasons, e.g., to optimize codon expression for a particular host (change codons in the human mRNA to those preferred by a bacterial host, such as, yeast or *E. coli*).

In a preferred embodiment, a polynucleotide encoding an albumin portion of an albumin fusion protein of the invention is optimized for expression in yeast or mammalian cells. In further preferred embodiment, a polynucleotide encoding a Therapeutic protein portion of an albumin fusion protein of the invention is optimized for expression in yeast or mammalian cells. In a still further preferred embodiment, a polynucleotide encoding an albumin fusion protein of the invention is optimized for expression in yeast or mammalian cells.

In an alternative embodiment, a codon optimized polynucleotide encoding a Therapeutic protein portion of an albumin fusion protein of the invention does not hybridize to the wild type polynucleotide encoding the Therapeutic protein under stringent hybridization conditions as described herein. In a further embodiment, a codon optimized polynucleotide encoding an albumin portion of an albumin fusion protein of the invention does not hybridize to the wild type polynucleotide encoding the albumin protein under stringent hybridization conditions as described herein. In another embodiment, a codon optimized polynucleotide encoding an albumin fusion protein of the invention does not hybridize to the wild type polynucleotide encoding the Therapeutic protein portin or the albumin protein portion under stringent hybridization conditions as described herein.

In an additional embodiment, polynucleotides encoding a Therapeutic protein portion of an albumin fusion protein of the invention do not comprise, or alternatively consist of, the

naturally occurring sequence of that Therapeutic protein. In a further embodiment, polynucleotides encoding an albumin protein portion of an albumin fusion protein of the invention do not comprise, or alternatively consist of, the naturally occurring sequence of albumin protein. In an alternative embodiment, polynucleotides encoding an albumin fusion protein of the invention do not comprise, or alternatively consist of, the naturally occurring sequence of a Therapeutic protein portion or the albumin protein portion.

5

10

15

20

25

30

35

Naturally occurring variants are called "allelic variants," and refer to one of several alternate forms of a gene occupying a given locus on a chromosome of an organism. (Genes II, Lewin, B., ed., John Wiley & Sons, New York (1985)). These allelic variants can vary at either the polynucleotide and/or polypeptide level and are included in the present invention. Alternatively, non-naturally occurring variants may be produced by mutagenesis techniques or by direct synthesis.

Using known methods of protein engineering and recombinant DNA technology, variants may be generated to improve or alter the characteristics of the polypeptides of the present invention. For instance, one or more amino acids can be deleted from the N-terminus or C-terminus of the polypeptide of the present invention without substantial loss of biological function. As an example, Ron et al. (J. Biol. Chem. 268: 2984-2988 (1993)) reported variant KGF proteins having heparin binding activity even after deleting 3, 8, or 27 amino-terminal amino acid residues. Similarly, Interferon gamma exhibited up to ten times higher activity after deleting 8-10 amino acid residues from the carboxy terminus of this protein. (Dobeli et al., J. Biotechnology 7:199-216 (1988).)

Moreover, ample evidence demonstrates that variants often retain a biological activity similar to that of the naturally occurring protein. For example, Gayle and coworkers (J. Biol. Chem. 268:22105-22111 (1993)) conducted extensive mutational analysis of human cytokine IL-1a. They used random mutagenesis to generate over 3,500 individual IL-1a mutants that averaged 2.5 amino acid changes per variant over the entire length of the molecule. Multiple mutations were examined at every possible amino acid position. The investigators found that "[m]ost of the molecule could be altered with little effect on either [binding or biological activity]." In fact, only 23 unique amino acid sequences, out of more than 3,500 nucleotide sequences examined, produced a protein that significantly differed in activity from wild-type.

Furthermore, even if deleting one or more amino acids from the N-terminus or C-terminus of a polypeptide results in modification or loss of one or more biological functions, other biological activities may still be retained. For example, the ability of a deletion variant to induce and/or to bind antibodies which recognize the secreted form will likely be retained when less than the majority of the residues of the secreted form are removed from the N-terminus or C-terminus. Whether a particular polypeptide lacking N- or C-terminal residues of a protein retains such immunogenic activities can readily be determined by routine methods

described herein and otherwise known in the art.

5

10

15

20

25

30

35

Thus, the invention further includes polypeptide variants which have a functional activity (e.g., biological activity and/or therapeutic activity). In highly preferred embodiments the invention provides variants of albumin fusion proteins that have a functional activity (e.g., biological activity and/or therapeutic activity, such as that disclosed in the "Biological Activity" column in Table 1) that corresponds to one or more biological and/or therapeutic activities of the Therapeutic protein corresponding to the Therapeutic protein portion of the albumin fusion protein. Such variants include deletions, insertions, inversions, repeats, and substitutions selected according to general rules known in the art so as have little effect on activity.

In preferred embodiments, the variants of the invention have conservative substitutions. By "conservative substitutions" is intended swaps within groups such as replacement of the aliphatic or hydrophobic amino acids Ala, Val, Leu and Ile; replacement of the hydroxyl residues Ser and Thr; replacement of the acidic residues Asp and Glu; replacement of the amide residues Asn and Gln, replacement of the basic residues Lys, Arg, and His; replacement of the aromatic residues Phe, Tyr, and Trp, and replacement of the small-sized amino acids Ala, Ser, Thr, Met, and Gly.

Guidance concerning how to make phenotypically silent amino acid substitutions is provided, for example, in Bowie et al., "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions," Science 247:1306-1310 (1990), wherein the authors indicate that there are two main strategies for studying the tolerance of an amino acid sequence to change.

The first strategy exploits the tolerance of amino acid substitutions by natural selection during the process of evolution. By comparing amino acid sequences in different species, conserved amino acids can be identified. These conserved amino acids are likely important for protein function. In contrast, the amino acid positions where substitutions have been tolerated by natural selection indicates that these positions are not critical for protein function. Thus, positions tolerating amino acid substitution could be modified while still maintaining biological activity of the protein.

The second strategy uses genetic engineering to introduce amino acid changes at specific positions of a cloned gene to identify regions critical for protein function. For example, site directed mutagenesis or alanine-scanning mutagenesis (introduction of single alanine mutations at every residue in the molecule) can be used. See Cunningham and Wells, Science 244:1081-1085 (1989). The resulting mutant molecules can then be tested for biological activity.

As the authors state, these two strategies have revealed that proteins are surprisingly tolerant of amino acid substitutions. The authors further indicate which amino acid changes

are likely to be permissive at certain amino acid positions in the protein. For example, most buried (within the tertiary structure of the protein) amino acid residues require nonpolar side chains, whereas few features of surface side chains are generally conserved. tolerated conservative amino acid substitutions involve replacement of the aliphatic or hydrophobic amino acids Ala, Val, Leu and Ile; replacement of the hydroxyl residues Ser and Thr; replacement of the acidic residues Asp and Glu; replacement of the amide residues Asn and Gln, replacement of the basic residues Lys, Arg, and His; replacement of the aromatic residues Phe, Tyr, and Trp, and replacement of the small-sized amino acids Ala, Ser, Thr. Met, and Gly. Besides conservative amino acid substitution, variants of the present invention include (i) polypeptides containing substitutions of one or more of the non-conserved amino acid residues, where the substituted amino acid residues may or may not be one encoded by the genetic code, or (ii) polypeptides containing substitutions of one or more of the amino acid residues having a substituent group, or (iii) polypeptides which have been fused with or chemically conjugated to another compound, such as a compound to increase the stability and/or solubility of the polypeptide (for example, polyethylene glycol), (iv) polypeptide containing additional amino acids, such as, for example, an IgG Fc fusion region peptide, . Such variant polypeptides are deemed to be within the scope of those skilled in the art from the teachings herein.

5

10

15

20

25

30.

35

For example, polypeptide variants containing amino acid substitutions of charged amino acids with other charged or neutral amino acids may produce proteins with improved characteristics, such as less aggregation. Aggregation of pharmaceutical formulations both reduces activity and increases clearance due to the aggregate's immunogenic activity. See Pinckard et al., Clin. Exp. Immunol. 2:331-340 (1967); Robbins et al., Diabetes 36: 838-845 (1987); Cleland et al., Crit. Rev. Therapeutic Drug Carrier Systems 10:307-377 (1993).

In specific embodiments, the polypeptides of the invention comprise; or alternatively, consist of, fragments or variants of the amino acid sequence of a Therapeutic protein described herein and/or human serum albumin, and/or albumin fusion protein of the invention, wherein the fragments or variants have 1-5, 5-10, 5-25, 5-50, 10-50 or 50-150, amino acid residue additions, substitutions, and/or deletions when compared to the reference amino acid sequence. In preferred embodiments, the amino acid substitutions are conservative. Nucleic acids encoding these polypeptides are also encompassed by the invention.

The polypeptide of the present invention can be composed of amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres, and may contain amino acids other than the 20 gene-encoded amino acids. The polypeptides may be modified by either natural processes, such as post-translational processing, or by chemical modification techniques which are well known in the art. Such modifications are well

described in basic texts and in more detailed monographs, as well as in a voluminous research Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched, for example, as a result of ubiquitination, and they may be cyclic, with or without-branching. Cyclic, branched, and branched cyclic polypeptides may result from posttranslation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphotidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristylation, oxidation, pegylation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. (See, for instance, PROTEINS - STRUCTURE AND MOLECULAR PROPERTIES, 2nd Creighton, W. H. Freeman and Company, New York (1993); POST-TRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B. C. Johnson, Ed., Academic Press, New York, pgs. 1-12 (1983); Seifter et al., Meth. Enzymol. 182:626-646 (1990); Rattan et al., Ann. N.Y. Acad. Sci. 663:48-62 (1992)).

Functional activity

5

10

15

20

25

30

35

"A polypeptide having functional activity" refers to a polypeptide capable of displaying one or more known functional activities associated with the full-length, proprotein, and/or mature form of a Therapeutic protein. Such functional activities include, but are not limited to, biological activity, antigenicity [ability to bind (or compete with a polypeptide for binding) to an anti-polypeptide antibody], immunogenicity (ability to generate antibody which binds to a specific polypeptide of the invention), ability to form multimers with polypeptides of the invention, and ability to bind to a receptor or ligand for a polypeptide.

"A polypeptide having biological activity" refers to a polypeptide exhibiting activity similar to, but not necessarily identical to, an activity of a Therapeutic protein of the present invention, including mature forms, as measured in a particular biological assay, with or without dose dependency. In the case where dose dependency does exist, it need not be identical to that of the polypeptide, but rather substantially similar to the dose-dependence in a

given activity as compared to the polypeptide of the present invention (i.e., the candidate polypeptide will exhibit greater activity or not more than about 25-fold less and, preferably, not more than about tenfold less activity, and most preferably, not more than about three-fold less activity relative to the polypeptide of the present invention).

In preferred embodiments, an albumin fusion protein of the invention has at least one biological and/or therapeutic activity associated with the Therapeutic protein (or fragment or variant thereof) when it is not fused to albumin.

5

10

. 15

20

25

30

35

The albumin fusion proteins of the invention can be assayed for functional activity (e.g., biological activity) using or routinely modifying assays known in the art, as well as assays described herein. Specifically, albumin fusion proteins may be assayed for functional activity (e.g., biological activity or therapeutic activity) using the assay referenced in the "Exemplary Activity Assay" column of Table 1. Additionally, one of skill in the art may routinely assay fragments of a Therapeutic protein corresponding to a Therapeutic protein portion of an albumin fusion protein of the invention, for activity using assays referenced in its corresponding row of Table 1. Further, one of skill in the art may routinely assay fragments of an albumin protein corresponding to an albumin protein portion of an albumin fusion protein of the invention, for activity using assays known in the art and/or as described in the Examples section below.

For example, in one embodiment where one is assaying for the ability of an albumin fusion protein of the invention to bind or compete with a Therapeutic protein for binding to antibody and/or anti-albumin antibody. anti-Therapeutic polypeptide immunoassays known in the art can be used, including but not limited to, competitive and non-competitive assay systems using techniques such as radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich" immunoassays, immunoradiometric assays, gel diffusion precipitation reactions, immunodiffusion assays, in situ immunoassays (using colloidal gold, enzyme or radioisotope labels, for example), western blots, precipitation reactions, agglutination assays (e.g., gel agglutination assays, hemagglutination assays), complement fixation assays, immunofluorescence assays, protein A assays, and immunoelectrophoresis assays, etc. In one embodiment, antibody binding is detected by detecting a label on the primary antibody. In another embodiment, the primary antibody is detected by detecting binding of a secondary antibody or reagent to the primary antibody. In a further embodiment, the secondary antibody is labeled. Many means are known in the art for detecting binding in an immunoassay and are within the scope of the present invention.

In a preferred embodiment, where a binding partner (e.g., a receptor or a ligand) of a Therapeutic protein is identified, binding to that binding partner by an albumin fusion protein containing that Therapeutic protein as the Therapeutic protein portion of the fusion can be assayed, e.g., by means well-known in the art, such as, for example, reducing and non-

reducing gel chromatography, protein affinity chromatography, and affinity blotting. See generally, Phizicky et al., Microbiol. Rev. 59:94-123 (1995). In another embodiment, the ability of physiological correlates of an albumin fusion protein of the present invention to bind to a substrate(s) of the Therapeutic polypeptide corresponding to the Therapeutic portion of the albumin fusion protein of the invention can be routinely assayed using techniques known in the art.

In an alternative embodiment, where the ability of an albumin fusion protein of the invention to multimerize is being evaluated, association with other components of the multimer can be assayed, e.g., by means well-known in the art, such as, for example, reducing and non-reducing gel chromatography, protein affinity chromatography, and affinity blotting. See generally, Phizicky et al., *supra*.

In addition, assays described herein (see Examples and Table 1) and otherwise known in the art may routinely be applied to measure the ability of albumin fusion proteins of the present invention and fragments, variants and derivatives thereof to elicit biological activity and/or Therapeutic activity (either *in vitro* or *in vivo*) related to either the Therapeutic protein portion and/or albumin portion of the albumin fusion protein of the present invention. Other methods will be known to the skilled artisan and are within the scope of the invention.

Albumin

5

10

15

25

30

35

As described above, an albumin fusion protein of the invention comprises at least a fragment or variant of a Therapeutic protein and at least a fragment or variant of human serum albumin, which are associated with one another, preferably by genetic fusion or chemical conjugation.

The terms, human serum albumin (HSA) and human albumin (HA) are used interchangeably herein. The terms, "albumin and "serum albumin" are broader, and encompass human serum albumin (and fragments and variants thereof) as well as albumin from other species (and fragments and variants thereof).

As used herein, "albumin" refers collectively to albumin protein or amino acid sequence, or an albumin fragment or variant, having one or more functional activities (e.g., biological activities) of albumin. In particular, "albumin" refers to human albumin or fragments thereof (see EP 201 239, EP 322 094 WO 97/24445, WO95/23857) especially the mature form of human albumin as shown in Figure 15 and SEQ ID NO:18, or albumin from other vertebrates or fragments thereof, or analogs or variants of these molecules or fragments thereof.

In preferred embodiments, the human serum albumin protein used in the albumin fusion proteins of the invention contains one or both of the following sets of point mutations with reference to SEQ ID NO:18: Leu-407 to Ala, Leu-408 to Val, Val-409 to Ala; and Arg-

410 to Ala; or Arg-410 to A, Lys-413 to Gln, and Lys-414 to Gln (see, e.g., International Publication No. WO95/23857, hereby incorporated in its entirety by reference herein). In even more preferred embodiments, albumin fusion proteins of the invention that contain one or both of above-described sets of point mutations have improved stability/resistance to yeast Yap3p proteolytic cleavage, allowing increased production of recombinant albumin fusion proteins expressed in yeast host cells.

5

.10

15

20

25

30

35

As used herein, a portion of albumin sufficient to prolong the therapeutic activity or shelf-life of the Therapeutic protein refers to a portion of albumin sufficient in length or structure to stabilize or prolong the therapeutic activity of the protein so that the shelf life of the Therapeutic protein portion of the albumin fusion protein is prolonged or extended compared to the shelf-life in the non-fusion state. The albumin portion of the albumin fusion proteins may comprise the full length of the HA sequence as described above or as shown in Figure 15, or may include one or more fragments thereof that are capable of stabilizing or prolonging the therapeutic activity. Such fragments may be of 10 or more amino acids in length or may include about 15, 20, 25, 30, 50, or more contiguous amino acids from the HA sequence or may include part or all of specific domains of HA. For instance, one or more fragments of HA spanning the first two immunoglobulin-like domains may be used.

The albumin portion of the albumin fusion proteins of the invention may be a variant of normal HA. The Therapeutic protein portion of the albumin fusion proteins of the invention may also be variants of the Therapeutic proteins as described herein. The term "variants" includes insertions, deletions and substitutions, either conservative or non conservative, where such changes do not substantially alter one or more of the oncotic, useful ligand-binding and non-immunogenic properties of albumin, or the active site, or active domain which confers the therapeutic activities of the Therapeutic proteins.

In particular, the albumin fusion proteins of the invention may include naturally occurring polymorphic variants of human albumin and fragments of human albumin, for example those fragments disclosed in EP 322 094 (namely HA (Pn), where n is 369 to 419). The albumin may be derived from any vertebrate, especially any mammal, for example human, cow, sheep, or pig. Non-mammalian albumins include, but are not limited to, hen and salmon. The albumin portion of the albumin fusion protein may be from a different animal than the Therapeutic protein portion.

Generally speaking, an HA fragment or variant will be at least 100 amino acids long, preferably at least 150 amino acids long. The HA variant may consist of or alternatively comprise at least one whole domain of HA, for example domains 1 (amino acids 1-194 of SEQ ID NO:18), 2 (amino acids 195-387 of SEQ ID NO:18), 3 (amino acids 388-585 of SEQ ID NO:18), 1 + 2 (1-387 of SEQ ID NO:18), 2 + 3 (195-585 of SEQ ID NO:18) or 1 + 3 (amino acids 1-194 of SEQ ID NO:18 + amino acids 388-585 of SEQ ID NO:18). Each

domain is itself made up of two homologous subdomains namely 1-105, 120-194, 195-291, 316-387, 388-491 and 512-585, with flexible inter-subdomain linker regions comprising residues Lys106 to Glu119, Glu292 to Va1315 and Glu492 to Ala511.

Preferably, the albumin portion of an albumin fusion protein of the invention comprises at least one subdomain or domain of HA or conservative modifications thereof. If the fusion is based on subdomains, some or all of the adjacent linker is preferably used to link to the Therapeutic protein moiety.

Albumin Fusion Proteins

5

10

15

20

25

30

35

The present invention relates generally to albumin fusion proteins and methods of treating, preventing, or ameliorating diseases or disorders. As used herein, "albumin fusion protein" refers to a protein formed by the fusion of at least one molecule of albumin (or a fragment or variant thereof) to at least one molecule of a Therapeutic protein (or fragment or variant thereof). An albumin fusion protein of the invention comprises at least a fragment or variant of a Therapeutic protein and at least a fragment or variant of human serum albumin, which are associated with one another, preferably by genetic fusion (i.e., the albumin fusion protein is generated by translation of a nucleic acid in which a polynucleotide encoding all or a portion of a Therapeutic protein is joined in-frame with a polynucleotide encoding all or a portion of albumin) or chemical conjugation to one another. The Therapeutic protein and albumin protein, once part of the albumin fusion protein, may be referred to as a "portion", "region" or "moiety" of the albumin fusion protein.

In one embodiment, the invention provides an albumin fusion protein comprising, or alternatively consisting of, a Therapeutic protein (e.g., as described in Table 1) and a serum albumin protein. In other embodiments, the invention provides an albumin fusion protein comprising, or alternatively consisting of, a biologically active and/or therapeutically active fragment of a Therapeutic protein and a serum albumin protein. In other embodiments, the invention provides an albumin fusion protein comprising, or alternatively consisting of, a biologically active and/or therapeutically active variant of a Therapeutic protein and a serum albumin protein. In preferred embodiments, the serum albumin protein component of the albumin fusion protein is the mature portion of serum albumin.

In further embodiments, the invention provides an albumin fusion protein comprising, or alternatively consisting of, a Therapeutic protein, and a biologically active and/or therapeutically active fragment of serum albumin. In further embodiments, the invention provides an albumin fusion protein comprising, or alternatively consisting of, a Therapeutic protein and a biologically active and/or therapeutically active variant of serum albumin. In preferred embodiments, the Therapeutic protein portion of the albumin fusion protein is the mature portion of the Therapeutic protein.

In further embodiments, the invention provides an albumin fusion protein comprising, or alternatively consisting of, a biologically active and/or therapeutically active fragment or variant of a Therapeutic protein and a biologically active and/or therapeutically active fragment or variant of serum albumin. In preferred embodiments, the invention provides an albumin fusion protein comprising, or alternatively consisting of, the mature portion of a Therapeutic protein and the mature portion of serum albumin.

5

10

15

20

25

30

35

Preferably, the albumin fusion protein comprises HA as the N-terminal portion, and a Therapeutic protein as the C-terminal portion. Alternatively, an albumin fusion protein comprising HA as the C-terminal portion, and a Therapeutic protein as the N-terminal portion may also be used.

In other embodiments, the albumin fusion protein has a Therapeutic protein fused to both the N-terminus and the C-terminus of albumin. In a preferred embodiment, the Therapeutic proteins fused at the N- and C- termini are the same Therapeutic proteins. In a preferred embodiment, the Therapeutic proteins fused at the N- and C- termini are different Therapeutic proteins fused at the N- and C- termini are different Therapeutic proteins which may be used to treat or prevent the same disease, disorder, or condition (e.g. as listed in the "Preferred Indication Y" column of Table 1). In another preferred embodiment, the Therapeutic proteins fused at the N- and C-termini are different Therapeutic proteins which may be used to treat or prevent diseases or disorders (e.g. as listed in the "Preferred Indication Y" column of Table 1) which are known in the art to commonly occur in patients simultaneously.

In addition to albumin fusion protein in which the albumin portion is fused N-terminal and/or C-terminal of the Therapeutic protein portion, albumin fusion proteins of the invention may also be produced by inserting the Therapeutic protein or peptide of interest (e.g., Therapeutic protein X as diclosed in Table 1) into an internal region of HA. For instance, within the protein sequence of the HA molecule a number of loops or turns exist between the end and beginning of α-helices, which are stabilized by disulphide bonds (see Figures 9-11). The loops, as determined from the crystal structure of HA (Fig. 13) (PDB identifiers 1AO6, 1BJ5, 1BKE, 1BMO, 1E7E to 1E7I and 1UOR) for the most part extend away from the body of the molecule. These loops are useful for the insertion, or internal fusion, of therapeutically active peptides, particularly those requiring a secondary structure to be functional, or Therapeutic proteins, to essentially generate an albumin molecule with specific biological activity.

Loops in human albumin structure into which peptides or polypeptides may be inserted to generate albumin fusion proteins of the invention include: Val54-Asn61, Thr76-Asp89, Ala92-Glu100, Gln170-Ala176, His247-Glu252, Glu266-Glu277, Glu280-His288, Ala362-Glu368, Lys439-Pro447, Val462-Lys475, Thr478-Pro486, and Lys560-Thr566. In

more preferred embodiments, peptides or polypeptides are inserted into the Val54-Asn61, Gln170-Ala176, and/or Lys560-Thr566 loops of mature human albumin (SEQ ID NO:18).

Peptides to be inserted may be derived from either phage display or synthetic peptide libraries screened for specific biological activity or from the active portions of a molecule with the desired function. Additionally, random peptide libraries may be generated within particular loops or by insertions of randomized peptides into particular loops of the HA molecule and in which all possible combinations of amino acids are represented.

Such library(s) could be generated on HA or domain fragments of HA by one of the following methods:

(a) randomized mutation of amino acids within one or more peptide loops of HA or HA domain fragments. Either one, more or all the residues within a loop could be mutated in this manner (for example see Fig. 10a);

10

15

20 -

25

30

35

- (b) replacement of, or insertion into one or more loops of HA or HA domain fragments (i.e., internal fusion) of a randomized peptide(s) of length X_n (where X is an amino acid and n is the number of residues (for example see Fig. 10b);
- (c) N-, C- or N- and C- terminal peptide/protein fusions in addition to (a) and/or (b).

The HA or HA domain fragment may also be made multifunctional by grafting the peptides derived from different screens of different loops against different targets into the same HA or HA domain fragment.

In preferred embodiments, peptides inserted into a loop of human serum albumin are peptide fragments or peptide variants of the Therapeutic proteins disclosed in Table 1. More particulary, the invention encompasses albumin fusion proteins which comprise peptide fragments or peptide variants at least 7 at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 20, at least 25, at least 30, at least 35, or at least 40 amino acids in length inserted into a loop of human serum albumin. The invention also encompasses albumin fusion proteins which comprise peptide fragments or peptide variants at least 7 at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 20, at least 25, at least 30, at least 35, or at least 7 at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 35, or at least 16, at least 17, at least 18, at least 20, at least 30, at least 35, or at least 40 amino acids fused to the C-terminus of human serum albumin.

Generally, the albumin fusion proteins of the invention may have one HA-derived region and one Therapeutic protein-derived region. Multiple regions of each protein, however, may be used to make an albumin fusion protein of the invention. Similarly, more than one Therapeutic protein may be used to make an albumin fusion protein of the invention.

For instance, a Therapeutic protein may be fused to both the N- and C-terminal ends of the HA. In such a configuration, the Therapeutic protein portions may be the same or different Therapeutic protein molecules. The structure of bifunctional albumin fusion proteins may be represented as: X-HA-Y or Y-HA-X.

For example, an anti-BLySTM scFv-HA-IFN α -2b fusion may be prepared to modulate the immune response to IFN α -2b by anti-BLySTM scFv. An alternative is making a bi (or even multi) functional dose of HA-fusions *e.g.* HA-IFN α -2b fusion mixed with HA-anti-BLySTM scFv fusion or other HA-fusions in various ratio's depending on function, half-life etc.

5

10

15

20

25

30

35

Bi- or multi-functional albumin fusion proteins may also be prepared to target the Therapeutic protein portion of a fusion to a target organ or cell type via protein or peptide at the opposite terminus of HA.

As an alternative to the fusion of known therapeutic molecules, the peptides could be obtained by screening libraries constructed as fusions to the N-, C- or N- and C- termini of HA, or domain fragment of HA, of typically 6, 8, 12, 20 or 25 or X_n (where X is an amino acid (aa) and n equals the number of residues) randomized amino acids, and in which all possible combinations of amino acids were represented. A particular advantage of this approach is that the peptides may be selected *in situ* on the HA molecule and the properties of the peptide would therefore be as selected for rather than, potentially, modified as might be the case for a peptide derived by any other method then being attached to HA.

Additionally, the albumin fusion proteins of the invention may include a linker peptide between the fused portions to provide greater physical separation between the moieties and thus maximize the accessibility of the Therapeutic protein portion, for instance, for binding to its cognate receptor. The linker peptide may consist of amino acids such that it is flexible or more rigid.

The linker sequence may be cleavable by a protease or chemically to yield the growth hormone related moiety. Preferably, the protease is one which is produced naturally by the host, for example the S. cerevisiae protease kex2 or equivalent proteases.

Therefore, as described above, the albumin fusion proteins of the invention may have the following formula R1-L-R2; R2-L-R1; or R1-L-R2-L-R1, wherein R1 is at least one Therapeutic protein, peptide or polypeptide sequence, and not necessarily the same Therapeutic protein, L is a linker and R2 is a serum albumin sequence.

In preferred embodiments, Albumin fusion proteins of the invention comprising a Therapeutic protein have extended shelf life compared to the shelf life the same Therapeutic protein when not fused to albumin. Shelf-life typically refers to the time period over which the therapeutic activity of a Therapeutic protein in solution or in some other storage

formulation, is stable without undue loss of therapeutic activity. Many of the Therapeutic proteins are highly labile in their unfused state. As described below, the typical shelf-life of these Therapeutic proteins is markedly prolonged upon incorporation into the albumin fusion protein of the invention.

Albumin fusion proteins of the invention with "prolonged" or "extended" shelf-life exhibit greater therapeutic activity relative to a standard that has been subjected to the same storage and handling conditions. The standard may be the unfused full-length Therapeutic protein. When the Therapeutic protein portion of the albumin fusion protein is an analog, a variant, or is otherwise altered or does not include the complete sequence for that protein, the prolongation of therapeutic activity may alternatively be compared to the unfused equivalent of that analog, variant, altered peptide or incomplete sequence. As an example, an albumin fusion protein of the invention may retain greater than about 100% of the therapeutic activity, or greater than about 105%, 110%, 120%, 130%, 150% or 200% of the therapeutic activity of a standard when subjected to the same storage and handling conditions as the standard when compared at a given time point.

Shelf-life may also be assessed in terms of therapeutic activity remaining after storage, normalized to therapeutic activity when storage began. Albumin fusion proteins of the invention with prolonged or extended shelf-life as exhibited by prolonged or extended therapeutic activity may retain greater than about 50% of the therapeutic activity, about 60%, 70%, 80%, or 90% or more of the therapeutic activity of the equivalent unfused Therapeutic protein when subjected to the same conditions. For example, as discussed in Example 1, an albumin fusion protein of the invention comprising hGH fused to the full length HA sequence may retain about 80% or more of its original activity in solution for periods of up to 5 weeks or more under various temperature conditions.

25

30

35

10

15

20

Expression of Fusion Proteins

The albumin fusion proteins of the invention may be produced as recombinant molecules by secretion from yeast, a microorganism such as a bacterium, or a human or animal cell line. Preferably, the polypeptide is secreted from the host cells. We have found that, by fusing the hGH coding sequence to the HA coding sequence, either to the 5' end or 3' end, it is possible to secrete the albumin fusion protein from yeast without the requirement for a yeast-derived pro sequence. This was surprising, as other workers have found that a yeast derived pro sequence was needed for efficient secretion of hGH in yeast.

For example, Hiramatsu *et al.* (Appl Environ Microbiol 56:2125 (1990); Appl Environ Microbiol 57:2052 (1991)) found that the N-terminal portion of the pro sequence in the *Mucor pusillus* rennin pre-pro leader was important. Other authors, using the MF α -1 signal, have always included the MF α -1 pro sequence when secreting hGH. The pro sequences were

believed to assist in the folding of the hGH by acting as an intramolecular chaperone. The present invention shows that HA or fragments of HA can perform a similar function.

Hence, a particular embodiment of the invention comprises a DNA construct encoding a signal sequence effective for directing secretion in yeast, particularly a yeast-derived signal sequence (especially one which is homologous to the yeast host), and the fused molecule of the first aspect of the invention, there being no yeast-derived pro sequence between the signal and the mature polypeptide.

5

10

15

. 20

25

30

35

The Saccharomyces cerevisiae invertase signal is a preferred example of a yeast-derived signal sequence.

Conjugates of the kind prepared by Poznansky et al., (FEBS Lett. 239:18 (1988)), in which separately-prepared polypeptides are joined by chemical cross-linking, are not contemplated.

The present invention also includes a cell, preferably a yeast cell transformed to express an albumin fusion protein of the invention. In addition to the transformed host cells themselves, the present invention also contemplates a culture of those cells, preferably a monoclonal (clonally homogeneous) culture, or a culture derived from a monoclonal culture, in a nutrient medium. If the polypeptide is secreted, the medium will contain the polypeptide, with the cells, or without the cells if they have been filtered or centrifuged away. Many expression systems are known and may be used, including bacteria (for example *E. coli* and *Bacillus subtilis*), yeasts (for example *Saccharomyces cerevisiae*, *Kluyveromyces lactis* and *Pichia pastoris*, filamentous fungi (for example *Aspergillus*), plant cells, animal cells and insect cells.

Preferred yeast strains to be used in the production of albumin fusion proteins are D88, DXY1 and BXP10. D88 [leu2-3, leu2-122, can1, pra1, ubc4] is a derivative of parent strain AH22his⁺ (also known as DB1; see, e.g., Sleep et al. Biotechnology 8:42-46 (1990)). The strain contains a leu2 mutation which allows for auxotropic selection of 2 micron-based plasmids that contain the LEU2 gene. D88 also exhibits a derepression of PRB1 in glucose excess. The PRB1 promoter is normally controlled by two checkpoints that monitor glucose levels and growth stage. The promoter is activated in wild type yeast upon glucose depletion and entry into stationary phase. Strain D88 exhibits the repression by glucose but maintains the induction upon entry into stationary phase. The PRA1 gene encodes a yeast vacuolar protease, YscA endoprotease A, that is localized in the ER. The UBC4 gene is in the ubiquitination pathway and is involved in targeting short lived and abnormal proteins for ubiquitin dependant degradation. Isolation of this ubc4 mutation was found to increase the copy number of an expression plasmid in the cell and cause an increased level of expression of a desired protein expressed from the plasmid (see, e.g., International Publication No. WO99/00504, hereby incorporated in its entirety by reference herein).

DXY1, a derivative of D88, has the following genotype: [leu2-3, leu2-122, can1, pra1, ubc4, ura3::yap3]. In addition to the mutations isolated in D88, this strain also has a knockout of the YAP3 protease. This protease causes cleavage of mostly di-basic residues (RR, RK, KR, KK) but can also promote cleavage at single basic residues in proteins. Isolation of this yap3 mutation resulted in higher levels of full length HSA production (see, e.g., U.S. Patent No. 5,965,386, and Kerry-Williams et al., Yeast 14:161-169 (1998), hereby incorporated in their entireties by reference herein).

BXP10 has the following genotype: leu2-3, leu2-122, can1, pra1, ubc4, ura3, yap3::URA3, lys2, hsp150::LYS2, pmt1::URA3. In addition to the mutations isolated in DXY1, this strain also has a knockout of the PMT1 gene and the HSP150 gene. The PMT1 gene is a member of the evolutionarily conserved family of dolichyl-phosphate-D-mannose protein O-mannosyltransferases (Pmts). The transmembrane topology of Pmt1p suggests that it is an integral membrane protein of the endoplasmic reticulum with a role in O-linked glycosylation. This mutation serves to reduce/eliminate O-linked glycosylation of HSA fusions (see, e.g., International Publication No. WO00/44772, hereby incorporated in its entirety by reference herein). Studies revealed that the Hsp150 protein is inefficiently separated from rHA by ion exchange chromatography. The mutation in the HSP150 gene removes a potential contaminant that has proven difficult to remove by standard purification techniques. See, e.g., U.S. Patent No. 5,783,423, hereby incorporated in its entirety by reference herein.

10

15

20

25

30

35

The desired protein is produced in conventional ways, for example from a coding sequence inserted in the host chromosome or on a free plasmid. The yeasts are transformed with a coding sequence for the desired protein in any of the usual ways, for example electroporation. Methods for transformation of yeast by electroporation are disclosed in Becker & Guarente (1990) *Methods Enzymol*. 194, 182.

Successfully transformed cells, *i.e.*, cells that contain a DNA construct of the present invention, can be identified by well known techniques. For example, cells resulting from the introduction of an expression construct can be grown to produce the desired polypeptide. Cells can be harvested and lysed and their DNA content examined for the presence of the DNA using a method such as that described by Southern (1975) *J. Mol. Biol.* 98, 503 or Berent *et al.* (1985) *Biotech.* 3, 208. Alternatively, the presence of the protein in the supernatant can be detected using antibodies.

Useful yeast plasmid vectors include pRS403-406 and pRS413-416 and are generally available from Stratagene Cloning Systems, La Jolla, CA 92037, USA. Plasmids pRS403, pRS404, pRS405 and pRS406 are Yeast Integrating plasmids (YIps) and incorporate the yeast selectable markers HIS3, 7RP1, LEU2 and URA3. Plasmids pRS413-416 are Yeast Centromere plasmids (Ycps).

Preferred vectors for making albumin fusion proteins for expression in yeast include pPPC0005, pScCHSA, pScNHSA, and pC4:HSA which are described in detail in Example 2. Figure 4 shows a map of the pPPC0005 plasmid that can be used as the base vector into which polynucleotides encoding Therapeutic proteins may be cloned to form HA-fusions. It contains a PRB1 S. cerevisiae promoter (PRB1p), a Fusion leader sequence (FL), DNA encoding HA (rHA) and an ADH1 S. cerevisiae terminator sequence. The sequence of the fusion leader sequence consists of the first 19 amino acids of the signal peptide of human serum albumin (SEQ ID NO:29) and the last five amino acids of the mating factor alpha 1 promoter (SLDKR, see EP-A-387 319 which is hereby incorporated by reference in its entirety.

The plasmids, pPPC0005, pScCHSA, pScNHSA, and pC4:HSA were deposited on April 11, 2001 at the American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209 and given accession numbers ATCC _____, ____, and _____, respectively. Another vector useful for expressing an albumin fusion protein in yeast the pSAC35 vector which is described in Sleep *et al.*, BioTechnology 8:42 (1990) which is hereby incorporated by reference in its entirety.

10

15

20

25

30

35

A variety of methods have been developed to operably link DNA to vectors via complementary cohesive termini. For instance, complementary homopolymer tracts can be added to the DNA segment to be inserted to the vector DNA. The vector and DNA segment are then joined by hydrogen bonding between the complementary homopolymeric tails to form recombinant DNA molecules.

Synthetic linkers containing one or more restriction sites provide an alternative method of joining the DNA segment to vectors. The DNA segment, generated by endonuclease restriction digestion, is treated with bacteriophage T4 DNA polymerase or E. coli DNA polymerase I, enzymes that remove protruding, γ-single-stranded termini with their 3' 5'-exonucleolytic activities, and fill in recessed 3'-ends with their polymerizing activities.

The combination of these activities therefore generates blunt-ended DNA segments. The blunt-ended segments are then incubated with a large molar excess of linker molecules in the presence of an enzyme that is able to catalyze the ligation of blunt-ended DNA molecules, such as bacteriophage T4 DNA ligase. Thus, the products of the reaction are DNA segments carrying polymeric linker sequences at their ends. These DNA segments are then cleaved with the appropriate restriction enzyme and ligated to an expression vector that has been cleaved with an enzyme that produces termini compatible with those of the DNA segment.

Synthetic linkers containing a variety of restriction endonuclease sites are commercially available from a number of sources including International Biotechnologies Inc, New Haven, CT, USA.

A desirable way to modify the DNA in accordance with the invention, if, for example,

HA variants are to be prepared, is to use the polymerase chain reaction as disclosed by Saiki et al. (1988) Science 239, 487-491. In this method the DNA to be enzymatically amplified is flanked by two specific oligonucleotide primers which themselves become incorporated into the amplified DNA. The specific primers may contain restriction endonuclease recognition sites which can be used for cloning into expression vectors using methods known in the art.

5

10

15

20

25

30

35

Exemplary genera of yeast contemplated to be useful in the practice of the present invention as hosts for expressing the albumin fusion proteins are Pichia (formerly classified Candida, Torulopsis, as Hansenula), Saccharomyces, Kluyveromyces, Aspergillus, Pachysolen, Zygosaccharomyces, Schizosaccharomyces, Citeromyces, Torulaspora, Debaromyces, Trichoderma, Cephalosporium, Humicola, Mucor, Neurospora, Yarrowia. Leucosporidium, Botryoascus, Sporidiobolus. Rhodosporidium, Metschunikowia, Endomycopsis, and the like. Preferred genera are those selected from the group consisting of Saccharomyces, Schizosaccharomyces, Kluyveromyces, Pichia and Torulaspora. Examples of Saccharomyces spp. are S. cerevisiae, S. italicus and S. rouxii.

Examples of Kluyveromyces spp. are K. fragilis, K. lactis and K. marxianus. A suitable Torulaspora species is T. delbrueckii. Examples of Pichia (Hansenula) spp. are P. angusta (formerly H. polymorpha), P. anomala (formerly H. anomala) and P. pastoris. Methods for the transformation of S. cerevisiae are taught generally in EP 251 744, EP 258 067 and WO 90/01063, all of which are incorporated herein by reference.

Preferred exemplary species of Saccharomyces include S. cerevisiae, S. italicus, S. diastaticus, and Zygosaccharomyces rouxii. Preferred exemplary species of Kluyveromyces include K. fragilis and K. lactis. Preferred exemplary species of Hansenula include H. polymorpha (now Pichia angusta), H. anomala (now Pichia anomala), and Pichia capsulata. Additional preferred exemplary species of Pichia include P. pastoris. Preferred exemplary species of Aspergillus include A. niger and A. nidulans. Preferred exemplary species of Yarrowia include Y. lipolytica. Many preferred yeast species are available from the ATCC. For example, the following preferred yeast species are available from the ATCC and are useful in the expression of albumin fusion proteins: Saccharomyces cerevisiae Hansen, teleomorph strain BY4743 yap3 mutant (ATCC Accession No. 4022731); Saccharomyces cerevisiae Hansen, teleomorph strain BY4743 hsp150 mutant (ATCC Accession No. 4021266); Saccharomyces cerevisiae Hansen, teleomorph strain BY4743 pmt1 mutant (ATCC Accession No. 4023792); Saccharomyces cerevisiae Hansen, teleomorph (ATCC Accession Nos. 20626; 44773; 44774; and 62995); Saccharomyces diastaticus Andrews et Gilliland ex van der Walt, teleomorph (ATCC Accession No. 62987); Kluyveromyces lactis (Dombrowski) van der Walt, teleomorph (ATCC Accession No. 76492); Pichia angusta (Teunisson et al.) Kurtzman, teleomorph deposited as Hansenula polymorpha de Morais et Maia, teleomorph (ATCC Accession No. 26012); Aspergillus niger van Tieghem, anamorph

(ATCC Accession No. 9029); Aspergillus niger van Tieghem, anamorph (ATCC Accession No. 16404); Aspergillus nidulans (Eidam) Winter, anamorph (ATCC Accession No. 48756); and Yarrowia lipolytica (Wickerham et al.) van der Walt et von Arx, teleomorph (ATCC Accession No. 201847).

5

10

15

20

25

30 -

35

Suitable promoters for S. cerevisiae include those associated with the PGKI gene, GAL1 or GAL10 genes, CYCI, PHO5, TRPI, ADHI, ADH2, the genes for glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, triose phosphate isomerase, phosphoglucose isomerase, glucokinase, alpha-mating factor pheromone, [a mating factor pheromone], the PRBI promoter, the GUT2 promoter, the GPDI promoter, and hybrid promoters involving hybrids of parts of 5' regulatory regions with parts of 5' regulatory regions of other promoters or with upstream activation sites (e.g. the promoter of EP-A-258 067).

Convenient regulatable promoters for use in *Schizosaccharomyces pombe* are the thiamine-repressible promoter from the nmt gene as described by Maundrell (1990) *J. Biol. Chem.* 265, 10857-10864 and the glucose repressible jbpl gene promoter as described by Hoffman & Winston (1990) *Genetics* 124, 807-816.

Methods of transforming *Pichia* for expression of foreign genes are taught in, for example, Cregg *et al.* (1993), and various Phillips patents (*e.g.* US 4 857 467, incorporated herein by reference), and *Pichia* expression kits are commercially available from Invitrogen BV, Leek, Netherlands, and Invitrogen Corp., San Diego, California. Suitable promoters include AOXI and AOX2. Gleeson *et al.* (1986) J. Gen. Microbiol. 132, 3459-3465 include information on *Hansenula* vectors and transformation, suitable promoters being MOX1 and FMD1; whilst EP 361 991, Fleer *et al.* (1991) and other-publications from Rhone-Poulenc Rorer teach how to express foreign proteins in *Kluyveromyces* spp., a suitable promoter being PGKI.

The transcription termination signal is preferably the 3' flanking sequence of a eukaryotic gene which contains proper signals for transcription termination and polyadenylation. Suitable 3' flanking sequences may, for example, be those of the gene naturally linked to the expression control sequence used, *i.e.* may correspond to the promoter. Alternatively, they may be different in which case the termination signal of the S. cerevisiae ADHI gene is preferred.

The desired albumin fusion protein may be initially expressed with a secretion leader sequence, which may be any leader effective in the yeast chosen. Leaders useful in S. cerevisiae include that from the mating factor α polypeptide (MF α -1) and the hybrid leaders of EP-A-387 319. Such leaders (or signals) are cleaved by the yeast before the mature albumin is released into the surrounding medium. Further such leaders include those of S. cerevisiae invertase (SUC2) disclosed in JP 62-096086 (granted as 911036516), acid

phosphatase (PH05), the pre-sequence of MF α -1, 0 glucanase (BGL2) and killer toxin; S. diastaticus glucoarnylase II; S. carlsbergensis α -galactosidase (MEL1); K. lactis killer toxin; and Candida glucoarnylase.

Additional Methods of Recombinant and Synthetic Production of Albumin Fusion Proteins

5

10

15

20

25

30

35

The present invention also relates to vectors containing a polynucleotide encoding an albumin fusion protein of the present invention, host cells, and the production of albumin fusion proteins by synthetic and recombinant techniques. The vector may be, for example, a phage, plasmid, viral, or retroviral vector. Retroviral vectors may be replication competent or replication defective. In the latter case, viral propagation generally will occur only in complementing host cells.

The polynucleotides encoding albumin fusion proteins of the invention may be joined to a vector containing a selectable marker for propagation in a host. Generally, a plasmid vector is introduced in a precipitate, such as a calcium phosphate precipitate, or in a complex with a charged lipid. If the vector is a virus, it may be packaged in vitro using an appropriate packaging cell line and then transduced into host cells.

The polynucleotide insert should be operatively linked to an appropriate promoter, such as the phage lambda PL promoter, the E. coli lac, trp, phoA and tac promoters, the SV40 early and late promoters and promoters of retroviral LTRs, to name a few. Other suitable promoters will be known to the skilled artisan. The expression constructs will further contain sites for transcription initiation, termination, and, in the transcribed region, a ribosome binding site for translation. The coding portion of the transcripts expressed by the constructs will preferably include a translation initiating codon at the beginning and a termination codon (UAA, UGA or UAG) appropriately positioned at the end of the polypeptide to be translated.

As indicated, the expression vectors will preferably include at least one selectable marker. Such markers include dihydrofolate reductase, G418, glutamine synthase, or neomycin resistance for eukaryotic cell culture, and tetracycline, kanamycin or ampicillin resistance genes for culturing in *E. coli* and other bacteria. Representative examples of appropriate hosts include, but are not limited to, bacterial cells, such as *E. coli*, Streptomyces and Salmonella typhimurium cells; fungal cells, such as yeast cells (e.g., Saccharomyces cerevisiae or Pichia pastoris (ATCC Accession No. 201178)); insect cells such as Drosophila S2 and Spodoptera Sf9 cells; animal cells such as CHO, COS,NSO, 293, and Bowes melanoma cells; and plant cells. Appropriate culture mediums and conditions for the above-described host cells are known in the art.

Among vectors preferred for use in bacteria include pQE70, pQE60 and pQE-9,